: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription

Articles published in Blood
Retrieve available abstracts of 837 articles:
HTML format

Single Articles

July 2021

JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
PubMed Abstract available

BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
PubMed Abstract available

KUTSCH N
CLL-IPI: valid in the era of oral inhibitors?
Blood. 2021;138:106-107.
PubMed

KRANC KR
The essential reading list for AML: the m6A transcripts.
Blood. 2021;138:6-7.
PubMed

June 2021

MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
PubMed Abstract available

KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
PubMed Abstract available

RUBNITZ JE, Kaspers GJL
How I treat pediatric acute myeloid leukemia.
Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
PubMed Abstract available

LV K, Ren JG, Han X, Gui J, et al
Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
PubMed Abstract available

MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
PubMed Abstract available

CHANG Y, Min J, Jarusiewicz J, Actis M, et al
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
PubMed Abstract available

EICHHORST B
Vaccination against COVID-19: a challenge in CLL.
Blood. 2021;137:3153-3154.
PubMed

BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
PubMed Abstract available

JONES RJ, DeBaun MR
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
PubMed Abstract available

TANAKA T, Morita K, Wang F, Loghavi S, et al
Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
PubMed Abstract available

DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
PubMed Abstract available

AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
PubMed Abstract available

STEVENSON FK, Forconi F, Kipps TJ
Exploring the Pathways to Chronic Lymphocytic Leukemia.
Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
PubMed Abstract available

May 2021

BORELLA G, Da Ros A, Borile G, Porcu E, et al
Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
PubMed Abstract available

VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
PubMed Abstract available

ESCRIBANO SERRAT S, Calo Perez A
Pure erythroid leukemia.
Blood. 2021;137:2709.
PubMed

SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
PubMed Abstract available

WIMMER J, Hurstel R
Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
Blood. 2021;137:2564.
PubMed

April 2021

SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
PubMed Abstract available

CHATZIDIMITRIOU C, Vassilakopoulos TP
Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
Blood. 2021;137:2272.
PubMed

DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
PubMed Abstract available

MITTELMAN SD, Kim J, Raca G, Li G, et al
Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.
PubMed

LEW TE, Tam CS, Seymour JF
How I treat chronic lymphocytic leukemia after venetoclax.
Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
PubMed Abstract available

DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
PubMed Abstract available

HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
PubMed Abstract available

AMES E, Silva O
Polytypic T-cell prolymphocytic leukemia.
Blood. 2021;137:2125.
PubMed

SANDBERG Y, Weerkamp F
Charcot-Leyden crystals in chronic eosinophilic leukemia.
Blood. 2021;137:1985.
PubMed

SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
PubMed Abstract available

March 2021

BYRD JC, Woyach JA, Furman RR, Martin P, et al
Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia.
Blood. 2021 Mar 30. pii: 475651. doi: 10.1182/blood.2020009617.
PubMed Abstract available

NIU X, Rothe K, Chen M, Grasedieck S, et al
Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia.
Blood. 2021 Mar 30. pii: 475648. doi: 10.1182/blood.2020007651.
PubMed Abstract available

OLSON TL, Cheon H, Xing JC, Olson KC, et al
Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.
Blood. 2021 Mar 30. pii: 475646. doi: 10.1182/blood.2020005831.
PubMed Abstract available

SEDA V, Vojackova E, Ondrisova L, Kostalova L, et al
FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia.
Blood. 2021 Mar 30. pii: 475649. doi: 10.1182/blood.2020008101.
PubMed Abstract available

ZHANG JP, Cheng T
Modeling acute erythroid leukemia via CRISPR.
Blood. 2021;137:1565-1567.
PubMed

CHANG H, Eladl E
Multiple Auer rods in a mixed-phenotype acute leukemia.
Blood. 2021;137:1702.
PubMed

JABBOUR E, Kantarjian H
A new era in the treatment of acute lymphoblastic leukemia.
Blood. 2021;137:1563-1564.
PubMed

FENG M, Xie X, Han G, Zhang T, et al
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.
Blood. 2021 Mar 24. pii: 475592. doi: 10.1182/blood.2020009676.
PubMed Abstract available

ROGERS KA, Andritsos LA, Wei L, McLaughlin E, et al
Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
Blood. 2021 Mar 22. pii: 475585. doi: 10.1182/blood.2020009688.
PubMed Abstract available

RASLAN O, Hsia CC
Cabot rings in acute myeloid leukemia.
Blood. 2021;137:1560.
PubMed

TCHENG M, Roma A, Ahmed N, Smith RW, et al
Very long chain fatty acid metabolism is required in acute myeloid leukemia.
Blood. 2021 Mar 15. pii: 475526. doi: 10.1182/blood.2020008551.
PubMed Abstract available

SAUER T, Parikh K, Sharma S, Omer B, et al
CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.
Blood. 2021 Mar 15. pii: 475523. doi: 10.1182/blood.2020008221.
PubMed Abstract available

MURALI I, Kasar S, Naeem A, Tyekucheva S, et al
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).
Blood. 2021 Mar 8. pii: 475459. doi: 10.1182/blood.2020006765.
PubMed Abstract available

TANG J, Yu J, Cai J, Zhang L, et al
Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
Blood. 2021 Mar 8. pii: 475463. doi: 10.1182/blood.2020010438.
PubMed Abstract available

NAZHA A
Should I rock the boat? When to stop TKIs in CML.
Blood. 2021;137:1136-1137.
PubMed

February 2021

DE MOERLOOSE B
CAR-T treatment of pediatric AML: a long and winding road.
Blood. 2021;137:1004-1006.
PubMed

MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood. 2021;137:1019-1023.
PubMed Abstract available

WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Blood. 2021;137:1037-1049.
PubMed Abstract available

HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Blood. 2021;137:1050-1060.
PubMed Abstract available

CHEN J, Sathiaseelan V, Moore AD, Tan S, et al
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
Blood. 2021 Feb 22. pii: 475287. doi: 10.1182/blood.2020009960.
PubMed Abstract available

Pediatric disease risk index for acute leukemia.
Blood. 2021;137:1001.
PubMed

QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
Blood. 2021;137:983-993.
PubMed Abstract available

SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
Blood. 2021;137:908-922.
PubMed Abstract available

LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Blood. 2021;137:939-944.
PubMed Abstract available

SCHMALBROCK LK, Dolnik A, Cocciardi S, Strang E, et al
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Blood. 2021 Feb 17. pii: 475246. doi: 10.1182/blood.2020007626.
PubMed Abstract available

HERBAUX C, Kornauth C, Poulain S, Chong SJF, et al
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood. 2021 Feb 17. pii: 475244. doi: 10.1182/blood.2020007303.
PubMed Abstract available

GILL S
DARTs point the way forward in AML.
Blood. 2021;137:720-721.
PubMed

NG AP
Unraveling a T-ALL Tapestri.
Blood. 2021;137:726-727.
PubMed

HERGOTT CB, Pozdnyakova O
Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
Blood. 2021;137:860.
PubMed

RAASTAD K, Huang Q
Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
Blood. 2021;137:718.
PubMed

GRANT S
Targeting cereblon in AML.
Blood. 2021;137:584-586.
PubMed

BROWN JR
AKT: a key to RT?
Blood. 2021;137:582-584.
PubMed

KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
Blood. 2021;137:646-660.
PubMed Abstract available

FALINI B, Brunetti L, Martelli MP
How I diagnose and treat NPM1-mutated AML.
Blood. 2021;137:589-599.
PubMed Abstract available

January 2021

GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.
Blood. 2021;137:569-572.
PubMed

RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
Blood. 2021;137:500-512.
PubMed Abstract available

SHOUVAL R, Soiffer RJ
Primum non nocere: allo-HSCT for AML in CR1.
Blood. 2021;137:438-439.
PubMed

COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
High frequency of clonal hematopoiesis in Erdheim-Chester disease.
Blood. 2021;137:485-492.
PubMed Abstract available

ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood. 2021;137:471-484.
PubMed Abstract available

SONG Q, Wang X, Wu X, Qin H, et al
Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Blood. 2021 Jan 27. pii: 475053. doi: 10.1182/blood.2020006345.
PubMed Abstract available

RIO-MACHIN A, Fitzgibbon J
Germline ETV6 variants: not ALL created equally.
Blood. 2021;137:288-289.
PubMed

GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood. 2021;137:323-335.
PubMed Abstract available

WEN Z, Yun G, Hebert A, Kong G, et al
NrasQ61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
Blood. 2021 Jan 19. pii: 475000. doi: 10.1182/blood.2020009082.
PubMed Abstract available

SHADMAN M, Ujjani C
Vaccinations in CLL: implications for COVID-19.
Blood. 2021;137:144-146.
PubMed

MERTENS D, Kronke J
Triggering T-cell activity in CLL.
Blood. 2021;137:150-151.
PubMed

MASS J, Alobeid B
Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
Blood. 2021;137:282.
PubMed

AL MOOSAWI M, Vercauteren S
Cerebrospinal fluid with unusual natural killer cell population.
Blood. 2021;137:281.
PubMed

IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Blood. 2021;137:216-231.
PubMed Abstract available

SALIB C, Hussein S
A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
Blood. 2021;137:142.
PubMed

SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
Blood. 2021;137:20-28.
PubMed Abstract available

KENNEDY E, Coulter EM, Halliwell E, Profitos-Peleja N, et al
TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.
Blood. 2021 Jan 7. pii: 474915. doi: 10.1182/blood.2020005964.
PubMed Abstract available

CORRE J
Undetectable MRD can change the deal.
Blood. 2021;137:5-6.
PubMed

KEESHAN K
Superenhancing AML with Trib1.
Blood. 2021;137:8-9.
PubMed

December 2020

MATTERN S, Nann D
Small lymphocytic leukemia with herpes simplex virus infection simulating metastatic cancer.
Blood. 2020;136:3087.
PubMed

KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Blood. 2020;136:3041-3050.
PubMed Abstract available

FURSTENAU M, Fink AM, Schilhabel A, Weiss J, et al
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.
Blood. 2020 Dec 23. pii: 474779. doi: 10.1182/blood.2020008609.
PubMed Abstract available

FAZIO G, Bardini M, de Lorenzo P, Grioni A, et al
RECURRENT GENETIC FUSIONS REDEFINE MLL-GERMLINE ACUTE LYMPHOBLASTIC LEUKEMIA IN INFANTS.
Blood. 2020 Dec 22. pii: 474771. doi: 10.1182/blood.2020009032.
PubMed

SLAGER SL, Lanasa MC, Marti GE, Achenbach SJ, et al
Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families.
Blood. 2020 Dec 21. pii: 474760. doi: 10.1182/blood.2020006322.
PubMed Abstract available

TARDIVON D, Antoszewski M, Zangger N, Nkosi M, et al
Notch Signaling Promotes Disease Initiation and Progression in Murine Chronic Lymphocytic Leukemia.
Blood. 2020 Dec 18. pii: 474750. doi: 10.1182/blood.2020006701.
PubMed Abstract available

MIAO H, Kim E, Chen D, Purohit T, et al
Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
Blood. 2020;136:2958-2963.
PubMed

LIU Y, Panetta JC, Yang W, Karol SE, et al
Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
Blood. 2020;136:2955-2958.
PubMed

HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Blood. 2020;136:2918-2926.
PubMed Abstract available

BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.
Blood. 2020;136:2764-2773.
PubMed Abstract available

PLATZBECKER U, Kordasti S
Natural born survivors: the inglorious TP53.
Blood. 2020;136:2727-2728.
PubMed

OBERBECK S, Schrader A, Warner K, Jungherz D, et al
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
Blood. 2020;136:2786-2802.
PubMed Abstract available

SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood. 2020;136:2812-2823.
PubMed Abstract available

STAUBER J, Greally J, Steidl U
Preleukemic and Leukemic Evolution at the Stem Cell Level.
Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
PubMed Abstract available

TASHAKORI M, Khoury JD
B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.
Blood. 2020;136:2720.
PubMed

LULLA P, Naik S, Vasileiou S, Tzannou I, et al
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.
Blood. 2020 Dec 3. pii: 474389. doi: 10.1182/blood.2020009471.
PubMed Abstract available

PLEYER C, Ali MA, Cohen JI, Tian X, et al
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Blood. 2020 Dec 1. pii: 474376. doi: 10.1182/blood.2020008758.
PubMed Abstract available

November 2020

CORTES J
How to manage CML patients with comorbidities.
Blood. 2020;136:2507-2512.
PubMed Abstract available

NADEU F, Royo R, Clot G, Duran-Ferrer M, et al
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Blood. 2020 Nov 19. pii: 474211. doi: 10.1182/blood.2020008311.
PubMed Abstract available

RAO S
RUNX1 and inv(16) are frenemies in AML.
Blood. 2020;136:2361-2362.
PubMed

PERL AE
MLL-menin and FLT3 inhibitors team up for AML.
Blood. 2020;136:2369-2370.
PubMed

DZAMA MM, Steiner M, Rausch J, Sasca D, et al
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Blood. 2020;136:2442-2456.
PubMed Abstract available

KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
PubMed Abstract available

SURKA C, Jin L, Mbong N, Lu CC, et al
CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells.
Blood. 2020 Nov 16. pii: 474181. doi: 10.1182/blood.2020008676.
PubMed Abstract available

WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
Blood. 2020;136:2319-2333.
PubMed Abstract available

SHARMA S, Pavlasova G, Seda V, Cerna K, et al
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
Blood. 2020 Nov 10. pii: 474127. doi: 10.1182/blood.2020005627.
PubMed Abstract available

CHEVILLON F, Clappier E, Arfeuille C, Cayuela JM, et al
Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia.
Blood. 2020 Nov 10. pii: 474130. doi: 10.1182/blood.2020007782.
PubMed Abstract available

RIBERA JM, Morgades M, Ciudad J, Montesinos P, et al
Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
Blood. 2020 Nov 4. pii: 474081. doi: 10.1182/blood.2020007311.
PubMed Abstract available

GOTTSCHALK HOJFELDT S, Grell K, Abrahamsson J, Lund B, et al
Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia.
Blood. 2020 Nov 4. pii: 474076. doi: 10.1182/blood.2020006583.
PubMed Abstract available

October 2020

ROY A
A "gut feeling" about precursor B-ALL.
Blood. 2020;136:1995-1996.
PubMed

YANG W, Devidas M, Liu Y, Smith C, et al
Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations.
Blood. 2020 Oct 26. pii: 469753. doi: 10.1182/blood.2020008471.
PubMed

DICKINS RA
Rerouting DOT1L inhibitors in leukemia.
Blood. 2020;136:1900-1901.
PubMed

NIEMANN CU
Cost-effectiveness targeting CLL.
Blood. 2020;136:1896-1898.
PubMed

PERNER F, Gadrey JY, Xiong Y, Hatton C, et al
Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.
Blood. 2020;136:1983-1988.
PubMed

COOK LB, Phillips AA
How I treat Adult T-cell leukemia/lymphoma.
Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
PubMed Abstract available

BRIVIO E, Locatelli F, Lopez-Yurda M, Malone A, et al
A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
Blood. 2020 Oct 16. pii: 469618. doi: 10.1182/blood.2020007848.
PubMed Abstract available

PASSARO D
Myeloid cells hold the master key for T-ALL spread.
Blood. 2020;136:1799-1800.
PubMed

INABA H, Pui CH
Intensive but tender care for infant ALL.
Blood. 2020;136:1797-1798.
PubMed

DUPLOYEZ N, Jamrog LA, Fregona V, Hamelle C, et al
Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.
Blood. 2020 Oct 9. pii: 464429. doi: 10.1182/blood.2020005756.
PubMed Abstract available

SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
Reduced-intensity therapy of pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction.
Blood. 2020 Oct 8. pii: 464272. doi: 10.1182/blood.2020007977.
PubMed Abstract available

GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow.
Blood. 2020 Oct 7. pii: 464167. doi: 10.1182/blood.2020006219.
PubMed

NIEMANN CU, Levin MD, Dubois J, Kersting S, et al
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Blood. 2020 Oct 7. pii: 464169. doi: 10.1182/blood.2020008608.
PubMed

BARKSDALE B, Leith CP
CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
Blood. 2020;136:1698.
PubMed

STARCZYNOWSKI DT
HHEX expression drives AML development.
Blood. 2020;136:1575-1576.
PubMed

TAKEDA R, Asada S, Park SJ, Yokoyama A, et al
HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Blood. 2020;136:1670-1684.
PubMed Abstract available

September 2020

WANG W, Thakral B
CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?
Blood. 2020;136:1565.
PubMed

THANGAVELU G, Wang C, Loschi M, Saha A, et al
Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses.
Blood. 2020 Sep 24. pii: 463979. doi: 10.1182/blood.2020005628.
PubMed Abstract available

TAYLOR J, Mi X, North K, Binder M, et al
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Blood. 2020;136:1477-1486.
PubMed Abstract available

PEPPER M, Tan B
Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia.
Blood. 2020;136:1467.
PubMed

Enshaei A, O'Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.
Blood. 2020;136:1468.
PubMed

PINA-OVIEDO S, Thanendrarajan S
Meningeosis myelomatosis.
Blood. 2020;136:1466.
PubMed

STENGER D, Stief TA, Kaeuferle T, Willier S, et al
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood. 2020;136:1407-1418.
PubMed Abstract available

UY GL, Aldoss I, Foster MC, Sayre PH, et al
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.
Blood. 2020 Sep 14. pii: 463757. doi: 10.1182/blood.2020007732.
PubMed Abstract available

ZHEN T, Cao Y, Ren G, Zhao L, et al
RUNX1 and CBFbeta-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Blood. 2020 Sep 14. pii: 463758. doi: 10.1182/blood.2020007747.
PubMed Abstract available

VICENTE DUENAS C, Janssen S, Oldenburg M, Auer F, et al
An intact gut microbiome protects genetically predisposed mice against leukemia.
Blood. 2020 Sep 10. pii: 463729. doi: 10.1182/blood.2019004381.
PubMed Abstract available

KAWABATA KC, Zong H, Meydan C, Wyman S, et al
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
Blood. 2020 Sep 10. pii: 463728. doi: 10.1182/blood.2019001745.
PubMed Abstract available

WILL B
No keto for AML stem cells!
Blood. 2020;136:1219-1221.
PubMed

MAMONKIN M
Detonating T-ALL.
Blood. 2020;136:1218-1219.
PubMed

YUSUF RZ, Saez B, Sharda A, van Gastel N, et al
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Blood. 2020;136:1303-1316.
PubMed Abstract available

SONG L, Yu B, Yang Y, Liang J, et al
Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.
Blood. 2020 Sep 8. pii: 463712. doi: 10.1182/blood.2020005622.
PubMed Abstract available

MONTSERRAT E
When CLL meets COVID-19.
Blood. 2020;136:1115-1116.
PubMed

MATO AR, Roeker LE, Lamanna N, Allan JN, et al
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood. 2020;136:1134-1143.
PubMed Abstract available

FULTANG L, Booth S, Yogev O, Martins da Costa B, et al
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.
Blood. 2020;136:1155-1160.
PubMed Abstract available

TEACHEY DT, Hunger SP, Loh ML
Optimizing Therapy in the Modern Age: Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia.
Blood. 2020 Sep 2. pii: 463610. doi: 10.1182/blood.2020007702.
PubMed Abstract available

SHANMUGANATHAN N, Pagani IS, Ross DM, Park S, et al
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Blood. 2020 Sep 1. pii: 463598. doi: 10.1182/blood.2020005514.
PubMed Abstract available

XIAO W, Chan A, Waarts MR, Mishra T, et al
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia.
Blood. 2020 Sep 1. pii: 463602. doi: 10.1182/blood.2020007897.
PubMed Abstract available

FENWARTH L, Thomas X, de Botton S, Duployez N, et al
A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.
Blood. 2020 Sep 1. pii: 463599. doi: 10.1182/blood.2020005524.
PubMed Abstract available

August 2020

TAN Y, Wang X, Song H, Zhang Y, et al
A PML/RARalpha direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
Blood. 2020 Aug 27. pii: 463523. doi: 10.1182/blood.2020005698.
PubMed Abstract available

WANG HY, Tzachanis D
Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
Blood. 2020;136:1112.
PubMed

LUEDKE C, Rein L
Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.
Blood. 2020;136:1113.
PubMed

DEWOLF S, Tallman MS
How I treat relapsed or refractory AML.
Blood. 2020;136:1023-1032.
PubMed Abstract available

FANG H, Xu J
Blastoid plasma cell leukemia mimicking acute leukemia.
Blood. 2020;136:1012.
PubMed

LIU H
NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy.
Blood. 2020;136:1011.
PubMed

MALINGE S
SNAIL trail in myeloid malignancies.
Blood. 2020;136:920-921.
PubMed

SPENCER DH
Deletions in BCP-ALL result in a TAD more FLT3.
Blood. 2020;136:919-920.
PubMed

CARMICHAEL CL, Wang J, Nguyen T, Kolawole O, et al
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
Blood. 2020;136:957-973.
PubMed Abstract available

ALBERTI-SERVERA L, Demeyer S, Govaerts I, Swings T, et al
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
Blood. 2020 Aug 18. pii: 463329. doi: 10.1182/blood.2020006996.
PubMed Abstract available

JOLLY CJ, Pimanda JE
Titans awake: HMAs for virus-driven ATL.
Blood. 2020;136:777-779.
PubMed

WATANABE T, Yamashita S, Ureshino H, Kamachi K, et al
Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Blood. 2020;136:871-884.
PubMed Abstract available

STROUBOULIS J
Erythroleukemia: all roads lead to GATA1?
Blood. 2020;136:648-649.
PubMed

FAGNAN A, Bagger FO, Pique-Borras MR, Ignacimouttou C, et al
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Blood. 2020;136:698-714.
PubMed Abstract available

GARCIA-MANERO G, Griffiths EA, Steensma DP, Roboz GJ, et al
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood. 2020;136:674-683.
PubMed Abstract available

RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
Prostaglandin E2 stimulates cAMP signaling and re-sensitizes human leukemia cells to glucocorticoid-induced cell death.
Blood. 2020 Aug 5. pii: 461709. doi: 10.1182/blood.2020005712.
PubMed Abstract available

July 2020

YOSHINO S, Yokoyama T, Sunami Y, Takahara T, et al
Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
Blood. 2020 Jul 30. pii: 461620. doi: 10.1182/blood.2019004586.
PubMed Abstract available

CARROLL M
A common protein target for an uncommon subtype of AML.
Blood. 2020;136:377-378.
PubMed

BEAUMONT AL, Suner L
Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement.
Blood. 2020;136:520.
PubMed

ASSAF N, Terre C
Double translocation or gene insertion? A BCR/ABL1 fusion in Philadelphia-negative CML.
Blood. 2020;136:521.
PubMed

SAAD M, Loh KP, Tooze JA, Pardee TS, et al
Geriatric assessment and survival among older adults receiving post-remission therapy for acute myeloid leukemia.
Blood. 2020 Jul 22. pii: 461543. doi: 10.1182/blood.2020005498.
PubMed

NISHII R, Baskin-Doerfler R, Yang W, Oak N, et al
Molecular Basis of ETV6-Mediated Predisposition to Childhood Acute Lymphoblastic Leukemia.
Blood. 2020 Jul 21. pii: 461432. doi: 10.1182/blood.2020006164.
PubMed Abstract available

BRADY SW, Ma X, Zhou BS, Pui CH, et al
Response to "Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?"
Blood. 2020 Jul 20. pii: 461427. doi: 10.1182/blood.2020008107.
PubMed

BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
PubMed Abstract available

PIVA E, Tosato F
Promyelocytic leukemia with basophil-like granules.
Blood. 2020;136:372.
PubMed

STOCK W
Thrombosis in ALL: a risk without clear mitigation.
Blood. 2020;136:264-265.
PubMed

MOLINA O, Vinyoles M, Granada I, Roca-Ho H, et al
Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL.
Blood. 2020;136:313-327.
PubMed Abstract available

MUJAHED H, Miliara S, Neddermeyer A, Bengtzen S, et al
AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
Blood. 2020;136:339-352.
PubMed Abstract available

TSURUTA Y, Karube K
Hodgkin and Reed-Sternberg-like cells infected with human T-cell leukemia virus type 1.
Blood. 2020;136:257.
PubMed

Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.
Blood. 2020;136:259.
PubMed

LYAPICHEV KA, Jelloul FZ
Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma.
Blood. 2020;136:258.
PubMed

TOMIZAWA D, Miyamura T, Imamura T, Watanabe T, et al
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Blood. 2020 Jul 7. pii: 461277. doi: 10.1182/blood.2019004741.
PubMed Abstract available

FRIEDRICH C, Barreau S
A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
Blood. 2020;136:148.
PubMed

THOMPSON PA
Occupy BTK: the key to controlling CLL.
Blood. 2020;136:4-6.
PubMed

LICHT JD
Oncogenesis by E2A-PBX1 in ALL: RUNX and more.
Blood. 2020;136:3-4.
PubMed

KHAN DH, Mullokandov M, Wu Y, Voisin V, et al
Mitochondrial carrier homolog 2 is necessary for AML survival.
Blood. 2020;136:81-92.
PubMed Abstract available

SUN C, Nierman P, Kendall EK, Cheung J, et al
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood. 2020;136:93-105.
PubMed Abstract available

FALINI B, Brunetti L, Sportoletti P, Martelli MP, et al
NPM1-mutated acute myeloid leukemia: from bench to bedside.
Blood. 2020 Jul 1. pii: 461241. doi: 10.1182/blood.2019004226.
PubMed Abstract available

June 2020

GAYNON PS, Orgel E, Ji L
Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?
Blood. 2020 Jun 30. pii: 461230. doi: 10.1182/blood.2020005258.
PubMed

BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.
Blood. 2020 Jun 29. pii: 461224. doi: 10.1182/blood.2020006374.
PubMed Abstract available

HUNGER SP, Raetz E
How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population.
Blood. 2020 Jun 26. pii: 461194. doi: 10.1182/blood.2019004043.
PubMed Abstract available

GIOTOPOULOS G, Huntly BJP
CML: new tools to answer old questions.
Blood. 2020;135:2327-2328.
PubMed

STANKOVIC T, Kwok M
Genetics in the era of targeted CLL therapy.
Blood. 2020;135:2333-2334.
PubMed

GEYER HL, Gazelka H, Mesa R
How I treat pain in hematologic malignancies safely with opioid therapy.
Blood. 2020;135:2354-2364.
PubMed Abstract available

TAUSCH E, Schneider C, Robrecht S, Zhang C, et al
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood. 2020;135:2402-2412.
PubMed Abstract available

MATSUMURA T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, et al
Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
Blood. 2020 Jun 23. pii: 461100. doi: 10.1182/blood.2019004292.
PubMed Abstract available

CUNEO A, Scarfo L, Reda G, Varettoni M, et al
CHRONIC LYMPHOCYTIC LEUKEMIA MANAGEMENT IN ITALY DURING THE COVID-19 PANDEMIC. A CAMPUS CLL REPORT.
Blood. 2020 Jun 19. pii: 461059. doi: 10.1182/blood.2020006854.
PubMed

RAFFEL S, Klimmeck D, Falcone M, Demir A, et al
Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells.
Blood. 2020 Jun 18. pii: 461031. doi: 10.1182/blood.2019003654.
PubMed Abstract available

Setd2 deficiency accelerated MDS-related leukemia.
Blood. 2020;135:2326.
PubMed

CRUZ HERNANDEZ D, Metzner M, de Groot AP, Usukhbayar B, et al
Sensitive, Rapid Diagnostic Test For Transient Abnormal Myelopoiesis and Myeloid Leukemia of Down Syndrome.
Blood. 2020 Jun 18. pii: 461036. doi: 10.1182/blood.2020005610.
PubMed

BROWN JR
Inverting the BTK-BCL2 order.
Blood. 2020;135:2205-2207.
PubMed

GRANTS JM, Wegrzyn J, Hui T, O'Neill K, et al
Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice.
Blood. 2020;135:2235-2251.
PubMed Abstract available

LIN VS, Lew TE, Handunnetti SM, Blombery P, et al
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood. 2020;135:2266-2270.
PubMed Abstract available

CHEN BY, Song J, Hu CL, Chen SB, et al
SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Blood. 2020;135:2271-2285.
PubMed Abstract available

EISFELD AK
ON TRacK towards novel targets in leukemia.
Blood. 2020;135:2117-2119.
PubMed

LOWENBERG B, Huls G
The long road: improving outcome in elderly "unfit" AML?
Blood. 2020;135:2114-2115.
PubMed

LUCAS F, Larkin K, Gregory CT, Orwick S, et al
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Blood. 2020;135:2192-2195.
PubMed

WEI AH, Montesinos P, Ivanov V, DiNardo CD, et al
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Blood. 2020;135:2137-2145.
PubMed Abstract available

DIRAL E, Mori S, Antolini L, Abruzzese E, et al
Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation.
Blood. 2020 Jun 9. pii: 460734. doi: 10.1182/blood.2019004371.
PubMed

PATEL K, Isufi I, Kothari S, Davidoff AJ, et al
Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia.
Blood. 2020 Jun 9. pii: 460741. doi: 10.1182/blood.2020004922.
PubMed Abstract available

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.
Blood. 2020;135:2111.
PubMed

RATNER L
Predicting the future: adult T-cell leukemia.
Blood. 2020;135:2013-2014.
PubMed

ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood. 2020 Jun 4. pii: 460669. doi: 10.1182/blood.2019004583.
PubMed Abstract available

AN J, Ko M
Decoding ribosomes to keep growing (in AML).
Blood. 2020;135:2015-2016.
PubMed

SAINI NY, Marin D, Ledesma C, Delgado R, et al
Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.
Blood. 2020 Jun 3. pii: 460671. doi: 10.1182/blood.2019004685.
PubMed

TRAN QUANG C, Zaniboni B, Humeau R, Lengline E, et al
Preclinical Efficacy of Humanized, non-FcgammaR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia.
Blood. 2020 Jun 1. pii: 460600. doi: 10.1182/blood.2019003801.
PubMed Abstract available

May 2020

Passet M, Boissel N, Sigaux F, et al; Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284.
Blood. 2020;135:2011.
PubMed

NEGRETE D, Huang Q
A striking case of iatrogenic granulocytic nuclear abnormality in the bone marrow.
Blood. 2020;135:2010.
PubMed

SCHRATZ KE, Haley L, Danoff SK, Blackford AL, et al
Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
Blood. 2020;135:1946-1956.
PubMed Abstract available

ABDO C, Thonier F, Simonin M, Kaltenbach S, et al
Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
Blood. 2020 May 21. pii: 456040. doi: 10.1182/blood.2020005613.
PubMed

SUNG PJ, Babushok DV
Born to RUNX1.
Blood. 2020;135:1824-1825.
PubMed

TAM CS, Seymour JF
A predictive tool for early-stage CLL.
Blood. 2020;135:1820-1821.
PubMed

SIMON L, Spinella JF, Yao CY, Lavallee VP, et al
High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Blood. 2020;135:1882-1886.
PubMed Abstract available

MENSSEN AJ, Walter MJ
Genetics of Progression from MDS to Secondary Leukemia.
Blood. 2020 May 19. pii: 456027. doi: 10.1182/blood.2019000942.
PubMed Abstract available

SUN L, Babushok DV
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Blood. 2020 May 19. pii: 456026. doi: 10.1182/blood.2019000940.
PubMed Abstract available

DUNBAR A, Rampal R, Levine RL
Secondary leukemia to myeloproliferative neoplasms.
Blood. 2020 May 19. pii: 456028. doi: 10.1182/blood.2019000943.
PubMed Abstract available

SOULIER J
Introduction to a review series on secondary leukemia.
Blood. 2020 May 19. pii: 456030. doi: 10.1182/blood.2019004171.
PubMed

SCOTT HS, Hahn CN, Brown AL
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
Blood. 2020 May 19. pii: 456025. doi: 10.1182/blood.2019000937.
PubMed Abstract available

JELINEK T, Zuchnicka J
Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Blood. 2020;135:1816.
PubMed

GEBRU MT, Atkinson JM, Young M, Zhang L, et al
Glucocorticoids enhance the anti-leukemic activity of FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
Blood. 2020 May 12. pii: 455305. doi: 10.1182/blood.2019003124.
PubMed Abstract available

SONG C, Ge Z, Ding Y, Tan BH, et al
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia.
Blood. 2020 May 12. pii: 455304. doi: 10.1182/blood.2019002655.
PubMed Abstract available

TULSTRUP M, Moriyama T, Jiang C, Grosjean M, et al
Effects of germline variants in DHFR and FPGS on methotrexate metabolism and relapse of leukemia.
Blood. 2020 May 11. pii: 455060. doi: 10.1182/blood.2020005064.
PubMed Abstract available

YANG M, Safavi S, Woodward EL, Duployez N, et al
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
Blood. 2020 May 8. pii: 454973. doi: 10.1182/blood.2019004684.
PubMed Abstract available

KATER AP, Melenhorst JJ
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
Blood. 2020;135:1611-1612.
PubMed

GERBY B, Hoang T
A targetable cue in T-cell malignancy.
Blood. 2020;135:1616-1617.
PubMed

RONNER L, Podoltsev N, Gotlib J, Heaney ML, et al
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Blood. 2020;135:1696-1703.
PubMed Abstract available

GAUTHIER J, Hirayama AV, Purushe J, Hay KA, et al
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Blood. 2020;135:1650-1660.
PubMed Abstract available

April 2020

DE DOMINICI M, Porazzi P, Xiao Y, Chao A, et al
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
Blood. 2020;135:1560-1573.
PubMed Abstract available

SCHMOELLERL J, Barbosa IAM, Eder T, Brandstoetter T, et al
CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia.
Blood. 2020 Apr 28. pii: 454667. doi: 10.1182/blood.2019003267.
PubMed Abstract available

LONG J, Jia MY, Fang WY, Chen XJ, et al
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Blood. 2020;135:1472-1483.
PubMed Abstract available

ENSHAEI A, O'Connor D, Bartram J, Hancock J, et al
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Blood. 2020;135:1438-1446.
PubMed Abstract available

KRAUSE DS
The Fox(o) and the HDAC.
Blood. 2020;135:1416-1417.
PubMed

WHITLOCK JA
Go with the flow: simplified MRD in LMIC ALL.
Blood. 2020;135:1414-1415.
PubMed

COOK LBM, Rowan AG
CD28 fusions: an opportunity for young ATL?
Blood. 2020;135:1415-1416.
PubMed

LIU H, Hu S
Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation.
Blood. 2020;135:1506.
PubMed

WIERDA WG, Tambaro FP
How I manage CLL with venetoclax-based treatments.
Blood. 2020;135:1421-1427.
PubMed Abstract available

CLESHAM K, Rao V, Bartram J, Ancliff P, et al
Blinatumomab for infant acute lymphoblastic leukemia.
Blood. 2020;135:1501-1504.
PubMed

YOSHIDA N, Shigemori K, Donaldson N, Trevisani C, et al
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.
Blood. 2020;135:1467-1471.
PubMed Abstract available

ORVAIN C, Balsat M, Tavernier E, Marolleau JP, et al
Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study.
Blood. 2020 Apr 22. pii: 454452. doi: 10.1182/blood.2020004919.
PubMed Abstract available

MARRA A, Martino G
Placental myeloid sarcoma.
Blood. 2020;135:1410.
PubMed

HAROCHE J, Cohen-Aubart F, Amoura Z
Erdheim-Chester disease.
Blood. 2020;135:1311-1318.
PubMed Abstract available

SCHETELIG J, Baldauf H, Heidenreich F, Massalski C, et al
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Blood. 2020;135:1386-1395.
PubMed Abstract available

PATNAIK MM, Sallman DA, Mangaonkar A, Heuer R, et al
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML).
Blood. 2020 Apr 15. pii: 454390. doi: 10.1182/blood.2019004352.
PubMed

PI WC, Wang J, Shimada M, Lin JW, et al
E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
Blood. 2020 Apr 10. pii: 454360. doi: 10.1182/blood.2019003312.
PubMed Abstract available

HSU A, Freeman N
The fertile field of "isomopic" immune dysregulation as a nidus for lymphoproliferative disorders.
Blood. 2020;135:1303.
PubMed

SAENZ DT, Fiskus W, Mill CP, Perera D, et al
Mechanistic basis and efficacy of targeting the beta-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Blood. 2020;135:1255-1269.
PubMed Abstract available

CONDOLUCI A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, et al
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.
Blood. 2020 Apr 8. pii: 454292. doi: 10.1182/blood.2019003453.
PubMed Abstract available

LIN H, Rothe K, Chen M, Wu A, et al
The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML.
Blood. 2020 Apr 8. pii: 454304. doi: 10.1182/blood.2019003636.
PubMed Abstract available

SIMKINS A, Dunleavy K
Tackling Burkitt when it's back.
Blood. 2020;135:1078-1080.
PubMed

GHANNAM JY, Xu X, Maric I, Dillon L, et al
Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.
Blood. 2020;135:1185-1188.
PubMed

March 2020

OTTEMA S, Mulet-Lazaro R, Beverloo HB, Erpelinck CAJ, et al
Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Blood. 2020 Mar 27. pii: 454178. doi: 10.1182/blood.2019003701.
PubMed Abstract available

GANG EJ, Kim HN, Hsieh YT, Ruan Y, et al
Integrin alpha6 mediates drug resistance of acute lymphoblastic B-cell leukemia.
Blood. 2020 Mar 27. pii: 454180. doi: 10.1182/blood.2019001417.
PubMed Abstract available

KLEIN E, Bidet A
MYC and KMT2A multiple extra copies in acute myeloid leukemia.
Blood. 2020;135:1070.
PubMed

JINNOUCHI F, Yamauchi T, Yurino A, Nunomura T, et al
Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.
Blood. 2020 Mar 23. pii: 452764. doi: 10.1182/blood.2019002194.
PubMed Abstract available

MATNANI R, Weissmann D
Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts.
Blood. 2020;135:974.
PubMed

ELITZUR S, Izraeli S
It takes a village to grow leukemia.
Blood. 2020;135:886-887.
PubMed

CHIANG MY
Tearing ATL apart to find HTLV's sinister plans.
Blood. 2020;135:887-889.
PubMed

TARLOCK K, Alonzo T, Wang YC, Gerbing RB, et al
Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia.
Blood. 2020 Mar 18. pii: 452717. doi: 10.1182/blood.2019004179.
PubMed

LI L, Mitra A, Cui K, Zhao B, et al
Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell Acute Lymphoblastic Leukemia.
Blood. 2020 Mar 16. pii: 452704. doi: 10.1182/blood.2019000794.
PubMed Abstract available

HASSERJIAN RP, Steensma DP, Graubert TA, Ebert BL, et al
Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.
Blood. 2020 Mar 13. pii: 452698. doi: 10.1182/blood.2019004770.
PubMed Abstract available

LIU W, Xu J
Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia.
Blood. 2020;135:880.
PubMed

ABRISQUETA P, Bosch F
Venetoclax-obinutuzumab: harnessing complexity.
Blood. 2020;135:788-789.
PubMed

MICHAELIS LC
BCL-2 inhibition and AML: can we best Darwin?
Blood. 2020;135:781-782.
PubMed

DINARDO CD, Tiong IS, Quaglieri A, MacRaild S, et al
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Blood. 2020;135:791-803.
PubMed Abstract available

KO TK, Javed A, Lee KL, Pathiraja TN, et al
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
Blood. 2020 Mar 10. pii: 452673. doi: 10.1182/blood.2020004834.
PubMed Abstract available

Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131(22):2475-2484.
Blood. 2020;135:780.
PubMed

ROWAN AG, Dillon R, Witkover A, Melamed A, et al
Evolution of retrovirus-infected premalignant T-cell clones prior to Adult T-cell leukemia/lymphoma diagnosis.
Blood. 2020 Mar 5. pii: 452636. doi: 10.1182/blood.2019002665.
PubMed Abstract available

CHONG SJF, Davids MS
Breaking through BCL-2 inhibition in CLL.
Blood. 2020;135:709-711.
PubMed

DAVER N
A bispecific approach to improving CAR T cells in AML.
Blood. 2020;135:703-704.
PubMed

FU CL, Diacovo MJ
Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen.
Blood. 2020;135:778.
PubMed

GOTTSCHALK A, Glauche I, Cicconi S, Clark RE, et al
Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
Blood. 2020;135:766-769.
PubMed

February 2020

DILLON R, Hills R, Freeman S, Potter N, et al
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood. 2020;135:680-688.
PubMed Abstract available

DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Blood. 2020;135:597-609.
PubMed Abstract available

PAULI C, Liu Y, Rohde C, Cui C, et al
Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for Acute Myeloid Leukemia cell proliferation.
Blood. 2020 Feb 25. pii: 452567. doi: 10.1182/blood.2019004121.
PubMed Abstract available

SOVERINI S, Bavaro L, De Benedittis C, Martelli M, et al
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood. 2020;135:534-541.
PubMed Abstract available

DE SMEDT R, Morscio J, Reunes L, Roels J, et al
Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
PubMed Abstract available

KAGOTHO E, Chang H
CML in megakaryocytic transformation and extramedullary infiltration.
Blood. 2020;135:514.
PubMed

STRATI P, Schlette EJ, Solis Soto LM, Duenas DE, et al
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Blood. 2020;135:510-513.
PubMed

ZHANG L, Li J, Xu H, Shao X, et al
Myc-Miz-1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpalpha and Cebpdelta.
Blood. 2020 Feb 7. pii: 441057. doi: 10.1182/blood.2019001863.
PubMed Abstract available

PEDROSA F, Coustan-Smith E, Zhou Y, Cheng C, et al
Reduced-dose-intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Blood. 2020 Feb 6. pii: 441001. doi: 10.1182/blood.2019004215.
PubMed Abstract available

CIUREA SO, Kongtim P, Varma A, Rondon G, et al
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Blood. 2020;135:449-452.
PubMed Abstract available

KWOK M, Oldreive C, Rawstron AC, Goel A, et al
Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
Blood. 2020;135:411-428.
PubMed Abstract available

January 2020

TISSINO E, Pozzo F, Benedetti D, Caldana C, et al
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Blood. 2020 Jan 31. pii: 440985. doi: 10.1182/blood.2019003179.
PubMed Abstract available

MARTINO G, Ascani S
Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia.
Blood. 2020;135:392.
PubMed

PAN J, Zuo S, Deng B, Xu X, et al
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.
Blood. 2020;135:387-391.
PubMed

AL-SAWAF O, Lilienweiss E, Bahlo J, Robrecht S, et al
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Blood. 2020 Jan 27. pii: 440962. doi: 10.1182/blood.2019003451.
PubMed

WONG R, Tan TK, Amanda S, Ngoc PCT, et al
Feed-forward Regulatory Loop Driven by IRF4 and NF-kappaB in Adult T-cell Leukemia/Lymphoma.
Blood. 2020 Jan 23. pii: 431345. doi: 10.1182/blood.2019002639.
PubMed Abstract available

BEZERRA MF, Lima AS, Pique-Borras MR, Silveira DR, et al
Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis.
Blood. 2020 Jan 23. pii: 440480. doi: 10.1182/blood.2019003339.
PubMed

ALDOSS I, Douer D
How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
Blood. 2020 Jan 23. pii: 440580. doi: 10.1182/blood.2019002477.
PubMed Abstract available

FABRE MA, McKerrell T, Zwiebel M, Vijayabaskar MS, et al
Concordance for clonal hematopoiesis is limited in elderly twins.
Blood. 2020;135:269-273.
PubMed Abstract available

HANSEN JW, Pedersen DA, Larsen LA, Husby S, et al
Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality.
Blood. 2020;135:261-268.
PubMed Abstract available

BARZ MJ, Hof J, Groeneveld-Krentz S, Loh JW, et al
Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Blood. 2020 Jan 22. pii: 431280. doi: 10.1182/blood.2019002499.
PubMed Abstract available

WOESSMANN W, Zimmermann M, Meinhardt A, Mueller S, et al
Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy.
Blood. 2020 Jan 21. pii: 431277. doi: 10.1182/blood.2019003591.
PubMed Abstract available

SPYRIDONIDIS A
How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation.
Blood. 2020 Jan 21. pii: 431276. doi: 10.1182/blood.2019003566.
PubMed Abstract available

HE X, Feng Z, Ma J, Ling S, et al
Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.
Blood. 2020 Jan 17. pii: 431045. doi: 10.1182/blood.2019002779.
PubMed Abstract available

BLOMBERY P, Thompson E, Nguyen T, Birkinshaw RW, et al
Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blood. 2020 Jan 17. pii: 431046. doi: 10.1182/blood.2019004205.
PubMed

MEYER SE
MicroRNA immunomodulating therapeutics.
Blood. 2020;135:155-156.
PubMed

HALE DA, Krause JR
Unexpected lymph node finding in a patient with essential thrombocythemia.
Blood. 2020;135:154.
PubMed

ALDOSS I, Forman SJ
How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
PubMed Abstract available

MORSCIO J, Van Vlierberghe P
Chemotherapy at the wheel of ALL relapse.
Blood. 2020;135:4-5.
PubMed

SWANSON HD, Panetta JC, Barker PJ, Liu Y, et al
Predicting success of desensitization after pegaspargase allergy.
Blood. 2020;135:71-75.
PubMed

LEVIS M, Shi W, Chang K, Laing C, et al
FLT3 inhibitors added to induction therapy induce deeper remissions.
Blood. 2020;135:75-78.
PubMed

WANG N, Hu X, Cao W, Li C, et al
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
Blood. 2020;135:17-27.
PubMed Abstract available

December 2019

FOURNIER E, Duployez N, Ducourneau B, Raffoux E, et al
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.
Blood. 2019 Dec 27. pii: 430032. doi: 10.1182/blood.2019003471.
PubMed Abstract available

BYRD JC, Wierda WG, Schuh A, Devereux S, et al
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood. 2019 Dec 26. pii: 430030. doi: 10.1182/blood.2018884940.
PubMed Abstract available

VASSILIOU GS
The curious incident of TdT-mediated mutations in AML.
Blood. 2019;134:2229-2231.
PubMed

BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT.
Blood. 2019;134:2291-2303.
PubMed Abstract available

ROBOZ GJ, DiNardo CD, Stein EM, de Botton S, et al
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood. 2019 Dec 16. pii: 429665. doi: 10.1182/blood.2019002140.
PubMed Abstract available

TRAER E
Reducing acetyl-CoA enhances BET inhibition.
Blood. 2019;134:2122-2123.
PubMed

GARDNER RA, Ceppi F, Rivers J, Annesley C, et al
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Blood. 2019;134:2149-2158.
PubMed Abstract available

DOHNER K, Thiede C, Jahn N, Panina E, et al
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
Blood. 2019 Dec 11. pii: 429642. doi: 10.1182/blood.2019002697.
PubMed Abstract available

STANULLA M, Cave H, Moorman AV
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
Blood. 2019 Dec 10. pii: 429640. doi: 10.1182/blood.2019000813.
PubMed Abstract available

SU YL, Wang X, Mann M, Adamus TP, et al
Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo.
Blood. 2019 Dec 5. pii: 429548. doi: 10.1182/blood.2019002045.
PubMed Abstract available

OLIN RL
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.
Blood. 2019;134:2013-2021.
PubMed Abstract available

November 2019

WENDTNER CM
CLL: deep dive for residual cells by NGS matters.
Blood. 2019;134:1883-1884.
PubMed

FENNELL KA, Bell CC, Dawson MA
Epigenetic therapies in acute myeloid leukemia: where to from here?
Blood. 2019;134:1891-1901.
PubMed Abstract available

THOMPSON PA, Srivastava J, Peterson C, Strati P, et al
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Blood. 2019;134:1951-1959.
PubMed Abstract available

DINARDO CD, Wei AH
How I treat acute myeloid leukemia in the era of new drugs.
Blood. 2019 Nov 25. pii: 428884. doi: 10.1182/blood.2019001239.
PubMed Abstract available

KAY NE, Hanson CA
B-cell prolymphocytic leukemia has 3 subsets.
Blood. 2019;134:1777-1778.
PubMed

MCCURDY SR, Luznik L
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.
Blood. 2019;134:1802-1810.
PubMed Abstract available

WOYACH JA
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Blood. 2019;134:1796-1801.
PubMed Abstract available

DWYRE DM, Osman M
AML with inv(16) with numerous Charcot-Leyden crystals.
Blood. 2019;134:1876.
PubMed

CHONG EA, Levine BL, Grupp SA, Davis MM, et al
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Blood. 2019;134:1873-1875.
PubMed

TEACHEY DT, O'Connor D
How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.
Blood. 2019 Nov 18. pii: 428813. doi: 10.1182/blood.2019001557.
PubMed Abstract available

CLAUDIANI S, Metelli S, Kamvar R, Szydlo R, et al
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).
Blood. 2019;134.
PubMed Abstract available

ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.
Blood. 2019;134.
PubMed Abstract available

TAM CS, Siddiqi T, Allan JN, Kipps TJ, et al
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.
Blood. 2019;134.
PubMed Abstract available

TANAKA T, Morita K, Wang F, Little L, et al
Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
Blood. 2019;134.
PubMed Abstract available

SHARMAN JP, Banerji V, Fogliatto LM, Herishanu Y, et al
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).
Blood. 2019;134.
PubMed Abstract available

STATLER A, Hobbs BP, Radivoyevitch T, Siebenaller C, et al
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.
Blood. 2019;134.
PubMed Abstract available

JAIN N, Keating MJ, Thompson PA, Ferrajoli A, et al
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).
Blood. 2019;134.
PubMed Abstract available

CIUREA SO, Varma A, Kongtim P, Srour S, et al
Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis.
Blood. 2019;134.
PubMed Abstract available

SHIMA H, Kada A, Tanizawa A, Yuza Y, et al
Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study).
Blood. 2019;134.
PubMed Abstract available

REA D, Nicolini FE, Tulliez M, Rousselot P, et al
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
Blood. 2019;134.
PubMed Abstract available

LINDSLEY RC, Gibson CJ, Murdock HM, Stone RM, et al
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).
Blood. 2019;134.
PubMed Abstract available

SHANAFELT TD, Wang V, Kay NE, Hanson CA, et al
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.
Blood. 2019;134.
PubMed Abstract available

DIRAL E, Le Coutre P, Gottardi EM, Elena C, et al
Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR.
Blood. 2019;134.
PubMed Abstract available

LAMPSON BL, Tyekucheva S, Crombie JL, Kim AI, et al
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).
Blood. 2019;134.
PubMed Abstract available

SMITH CC, Levis MJ, Perl AE, Martinelli G, et al
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.
Blood. 2019;134.
PubMed Abstract available

RADICH J, Yeung C, Wu D
New approaches to molecular monitoring in CML (and other diseases).
Blood. 2019;134:1578-1584.
PubMed Abstract available

TARUMOTO Y, Lin S, Wang J, Milazzo JP, et al
Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
Blood. 2019 Nov 1. pii: 422697. doi: 10.1182/blood.2019001576.
PubMed Abstract available

October 2019

DUPLOYEZ N, Willekens C, Plo I, Marceau-Renaut A, et al
Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
Blood. 2019 Oct 31. pii: 422691. doi: 10.1182/blood.2019003206.
PubMed

SUN YM, Wang WT, Zeng ZC, Chen TQ, et al
circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
Blood. 2019;134:1533-1546.
PubMed Abstract available

LI B, Brady SW, Ma X, Shen S, et al
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Blood. 2019 Oct 24. pii: 422540. doi: 10.1182/blood.2019002220.
PubMed Abstract available

SANDERS MA
Lifting the veil on germline DDX41 mutations.
Blood. 2019;134:1368-1370.
PubMed

PHILLIPS AA
A sobering "check" on immune checkpoint inhibitors.
Blood. 2019;134:1366-1367.
PubMed

BURT R, Dey A, Aref S, Aguiar M, et al
Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Blood. 2019;134:1415-1429.
PubMed Abstract available

SEBERT M, Passet M, Raimbault A, Rahme R, et al
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
Blood. 2019;134:1441-1444.
PubMed Abstract available

BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
Terminal Deoxynucleotidyl Transferase Promotes Acute Myeloid Leukemia By Priming FLT3-ITD Replication Slippage.
Blood. 2019 Oct 17. pii: 421184. doi: 10.1182/blood.2019001238.
PubMed Abstract available

FIELDING AK
En-Abl-ing treatment of "Ph-like" ALL?
Blood. 2019;134:1277-1278.
PubMed

THANGAVELU G, Du J, Paz KG, Loschi M, et al
Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.
Blood. 2019 Oct 15. pii: 387148. doi: 10.1182/blood.2019000032.
PubMed Abstract available

PATEL AB, Franzini A, Leroy E, Kim SJ, et al
JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Blood. 2019 Oct 11. pii: 381160. doi: 10.1182/blood.2019001385.
PubMed Abstract available

MUSHTAQ MU, Matson DR
Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis.
Blood. 2019;134:1270.
PubMed

JIANG Y, Hu T, Wang T, Shi X, et al
AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia.
Blood. 2019 Oct 10. pii: 375147. doi: 10.1182/blood.2019001076.
PubMed Abstract available

ELITZUR S, Izraeli S
Genes driving bad luck.
Blood. 2019;134:1199-1200.
PubMed

RISITANO AM
T-PLL: harmonizing criteria for research.
Blood. 2019;134:1113-1114.
PubMed

MORISHIMA T, Krahl AC, Nasri M, Xu Y, et al
LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
Blood. 2019;134:1159-1175.
PubMed Abstract available

September 2019

Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
Blood. 2019;134:1111.
PubMed

SUKSWAI N, Thirabanjasak D
B-lymphoblastic leukemia/lymphoma with an unusual appendiceal involvement.
Blood. 2019;134:1110.
PubMed

LUNNING M, Vose J, Nastoupil L, Fowler N, et al
Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Blood. 2019 Sep 26. pii: blood.2019002118. doi: 10.1182/blood.2019002118.
PubMed Abstract available

RUCKER FG, Agrawal M, Corbacioglu A, Weber D, et al
Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.
Blood. 2019 Sep 25. pii: blood.2019001425. doi: 10.1182/blood.2019001425.
PubMed Abstract available

PATEL K, Danilov A, Pagel JM
Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
Blood. 2019 Sep 25. pii: blood.2019001795. doi: 10.1182/blood.2019001795.
PubMed Abstract available

KHATRI SS, Kim AS
Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma.
Blood. 2019;134:993.
PubMed

ASSLABER D, Qi Y, Maeding N, Steiner M, et al
B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion.
Blood. 2019 Sep 19. pii: blood.2019000973. doi: 10.1182/blood.2019000973.
PubMed Abstract available

GONZALEZ-GARCIA S, Mosquera M, Fuentes P, Palumbo T, et al
IL-7R is essential for leukemia-initiating cell activity and pathogenesis of T-cell acute lymphoblastic leukemia.
Blood. 2019 Sep 17. pii: blood.2019000982. doi: 10.1182/blood.2019000982.
PubMed Abstract available

CHAPIRO E, Pramil E, Diop M, Roos-Weil D, et al
Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Blood. 2019 Sep 16. pii: blood.2019001187. doi: 10.1182/blood.2019001187.
PubMed Abstract available

JULIUSSON G, Hagberg O, Lazarevic VL, Olander E, et al
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.
Blood. 2019 Sep 12. pii: blood.2019001728. doi: 10.1182/blood.2019001728.
PubMed

PARK CS, Lewis AH, Chen TJ, Bridges CS, et al
KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.
Blood. 2019 Sep 12. pii: blood.2018875922. doi: 10.1182/blood.2018875922.
PubMed Abstract available

HASSERJIAN RP
Illuminating neutrophilic myeloid neoplasms.
Blood. 2019;134:846-848.
PubMed

TAM CS, Trotman J, Opat S, Burger JA, et al
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood. 2019;134:851-859.
PubMed Abstract available

BATTIPAGLIA G, Labopin M, Kroger N, Vitek A, et al
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
Blood. 2019;134:892-899.
PubMed Abstract available

BUENO C, Tejedor JR, Bashford-Rogers R, Gonzalez-Silva L, et al
Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL.
Blood. 2019;134:900-905.
PubMed

HIJIYA N, Maschan A, Rizzari C, Shimada H, et al
Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Blood. 2019 Sep 11. pii: blood.2019000069. doi: 10.1182/blood.2019000069.
PubMed Abstract available

BROUX M, Prieto C, Demeyer S, Vanden Bempt M, et al
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Blood. 2019 Sep 6. pii: blood.2019000015. doi: 10.1182/blood.2019000015.
PubMed Abstract available

STEPHENS DM
Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia.
Blood. 2019 Sep 5. pii: blood.2019001750. doi: 10.1182/blood.2019001750.
PubMed Abstract available

August 2019

LEFEBVRE T, Mauvieux L
A gelatinous leukemia.
Blood. 2019;134:785.
PubMed

RAUCH DA, Conlon KC, Janakiram M, Brammer JE, et al
Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade.
Blood. 2019 Aug 29. pii: blood.2019002038. doi: 10.1182/blood.2019002038.
PubMed Abstract available

PERL AE
Availability of FLT3 inhibitors: how do we use them?
Blood. 2019;134:741-745.
PubMed Abstract available

Steele AJ, Prentice AG, Hoffbrand AV, et al. 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood. 2009;114(6):1217-1225.
Blood. 2019;134:719-721.
PubMed

WANG HY, Hinds BR
Cutaneous composite small lymphocytic lymphoma and primary cutaneous follicle center lymphoma.
Blood. 2019;134:717.
PubMed

TANASI I, Ba I, Sirvent N, Braun T, et al
Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements.
Blood. 2019 Aug 21. pii: blood.2019001244. doi: 10.1182/blood.2019001244.
PubMed

Oral arsenic for acute promyelocytic leukemia.
Blood. 2019;134:659.
PubMed

QUINQUENEL A, Fornecker LM, Letestu R, Ysebaert L, et al
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Blood. 2019;134:641-644.
PubMed Abstract available

JANKE LJ, Van Driest SL, Portera MV, Atreya RV, et al
Hypertension is a modifiable risk-factor for osteonecrosis in acute lymphoblastic leukemia.
Blood. 2019 Aug 13. pii: blood.2019000006. doi: 10.1182/blood.2019000006.
PubMed

CHEN Y, Chen L, Yu J, Ghia EM, et al
Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-kappaB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia.
Blood. 2019 Aug 13. pii: blood.2019001366. doi: 10.1182/blood.2019001366.
PubMed Abstract available

ZHU Y, He X, Lin YC, Dong H, et al
Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.
Blood. 2019 Aug 8. pii: blood.2019002457. doi: 10.1182/blood.2019002457.
PubMed Abstract available

VENDITTI A, Piciocchi A, Candoni A, Melillo L, et al
GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.
Blood. 2019 Aug 8. pii: blood.2018886960. doi: 10.1182/blood.2018886960.
PubMed Abstract available

GRITSMAN K
FLT3-ITD gets by with a little help from PRMT1.
Blood. 2019;134:498-500.
PubMed

KLEIN U
Resolving PI3K-delta inhibitor resistance in CLL.
Blood. 2019;134:496-498.
PubMed

COFFY S, Shi M
Giant intracytoplasmic inclusions in a T-cell large granular lymphocytic leukemia patient with acute severe anemia.
Blood. 2019;134:492.
PubMed

CHIANG CL, Goswami S, Frissora FW, Xie Z, et al
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Blood. 2019;134:432-444.
PubMed Abstract available

July 2019

BROWN AL, de Smith AJ, Gant VU, Yang W, et al
Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome.
Blood. 2019 Jul 26. pii: blood.2018890764. doi: 10.1182/blood.2018890764.
PubMed Abstract available

HERMANS SJF, Sandberg Y
T-cell prolymphocytic leukemia presenting as ascites.
Blood. 2019;134:411.
PubMed

STUANI L, Sarry JE
Help from outside: cysteine to survive in AML.
Blood. 2019;134:336-338.
PubMed

VASSILIOU GS
Triple-mutant AML: too clever by HLF?
Blood. 2019;134:222-224.
PubMed

CHIANG MY
Finding ARIEL under the sea of T-ALL circuits.
Blood. 2019;134:219-221.
PubMed

LI W, Cooley LD, August KJ, Richardson AI, et al
Cuplike nuclear morphology is highly associated with IKZF1 deletion in pediatric precursor B-cell ALL.
Blood. 2019;134:324-329.
PubMed

GOCHO Y, Yang JJ
Genetic Defects in Hematopoietic Transcription Factors and Predisposition to Acute Lymphoblastic Leukemia.
Blood. 2019 Jul 16. pii: blood.2018852400. doi: 10.1182/blood.2018852400.
PubMed Abstract available

VOGIATZI F, Winterberg D, Lenk L, Buchmann S, et al
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
Blood. 2019 Jul 16. pii: blood.2019000904. doi: 10.1182/blood.2019000904.
PubMed

ROSSI D
Quest of biomarkers for venetoclax-treated CLL.
Blood. 2019;134:97-98.
PubMed

STABER PB, Herling M, Bellido M, Jacobsen ED, et al
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).
Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402.
PubMed Abstract available

GIACOPELLI B, Zhao Q, Ruppert AS, Agyeman A, et al
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.
Blood. 2019 Jul 10. pii: blood.2019000490. doi: 10.1182/blood.2019000490.
PubMed Abstract available

LUCENA-ARAUJO AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR MD, et al
Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.
Blood. 2019 Jul 10. pii: blood.2019000239. doi: 10.1182/blood.2019000239.
PubMed Abstract available

Nguyen TD, Shaid S, Vakhrusheva O, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. Blood. 2019;133(2):168-179.
Blood. 2019;134:94.
PubMed

MILL CP, Fiskus W, DiNardo CD, Qian Y, et al
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Blood. 2019;134:59-73.
PubMed Abstract available

SHANMUGANATHAN N, Braley JA, Yong ASM, Hiwase DK, et al
Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.
Blood. 2019;134:85-89.
PubMed

HU T, Morita K, Hill MC, Jiang Y, et al
PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells.
Blood. 2019 Jul 3. pii: blood.2018888255. doi: 10.1182/blood.2018888255.
PubMed Abstract available

June 2019

DI PAOLA J, Porter CC
ETV6-Related Thrombocytopenia and Leukemia Predisposition.
Blood. 2019 Jun 27. pii: blood.2019852418. doi: 10.1182/blood.2019852418.
PubMed Abstract available

COUTRE S
A one-two punch with VO KOs CLL.
Blood. 2019;133:2737-2738.
PubMed

ROTUNNO G, Mannarelli C, Brogi G, Pacilli A, et al
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.
Blood. 2019;133:2802-2808.
PubMed

GODLEY LA
FouNdER mutations confer risk for leukemias.
Blood. 2019;133:2636-2638.
PubMed

HEUSER M, Lai CK
Message from the void: MRD analysis from ctDNA.
Blood. 2019;133:2631-2633.
PubMed

CHIODIN G, Forconi F
Hedgehog activation in CLL.
Blood. 2019;133:2628-2630.
PubMed

HE X, Zhu Y, Lin YC, Li M, et al
PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) Acute Myeloid Leukemia.
Blood. 2019 Jun 19. pii: blood.2019001282. doi: 10.1182/blood.2019001282.
PubMed Abstract available

Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.
Blood. 2019;133:2625.
PubMed

KWON R, Duffield AS
HTLV-1-associated adult T-cell leukemia/lymphoma with disseminated strongyloidiasis.
Blood. 2019;133:2623.
PubMed

YOSHIMOTO M
B-1 progenitor acute lymphoid leukemia.
Blood. 2019;133:2557-2558.
PubMed

RUDORF A, Muller TA, Klingeberg C, Kreutmair S, et al
NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.
Blood. 2019 Jun 11. pii: blood.2018883140. doi: 10.1182/blood.2018883140.
PubMed Abstract available

May 2019

AHN IE, Basumallik N, Tian X, Soto S, et al
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Blood. 2019;133:2452-2455.
PubMed

EDITORIAL OFFICE B
RETRACTION: Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006
Blood. 2019 May 24. pii: blood-2019-05-901215. doi: 10.1182/blood-2019-05-901215
PubMed

SYKES SM
NCAM1 supports therapy resistance and LSC function in AML.
Blood. 2019;133:2247-2248.
PubMed

MACIOCIA PM, Pule MA
Anti-CD1a CAR T cells to selectively target T-ALL.
Blood. 2019;133:2246-2247.
PubMed

DIECK CL, Ferrando A
Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Blood. 2019;133:2263-2268.
PubMed Abstract available

SASCA D, Szybinski J, Schuler A, Shah V, et al
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
Blood. 2019;133:2305-2319.
PubMed Abstract available

ZHU HH, Hu J, Lo Coco F, Jin J, et al
The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.
Blood. 2019 May 21. pii: blood.2019000760. doi: 10.1182/blood.2019000760.
PubMed Abstract available

JONES CL, Stevens BM, D'Alessandro A, Culp-Hill R, et al
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.
Blood. 2019 May 17. pii: blood.2019898114. doi: 10.1182/blood.2019898114.
PubMed Abstract available

YANG J, Gabali A
Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome.
Blood. 2019;133:2243.
PubMed

MAGGI M, Scotti C
HAP1 loss in l-asparaginase resistance.
Blood. 2019;133:2116-2118.
PubMed

LEE JK, Kang S, Wang X, Rosales JL, et al
HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.
Blood. 2019;133:2222-2232.
PubMed Abstract available

KARSCHNIA P, Jordan JT, Forst DA, Arrillaga-Romany IC, et al
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Blood. 2019;133:2212-2221.
PubMed Abstract available

VAN BRUGGEN JAC, Martens AWJ, Fraietta JA, Hofland T, et al
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.
Blood. 2019 May 10. pii: blood.2018885863. doi: 10.1182/blood.2018885863.
PubMed Abstract available

GARG S, Reyes-Palomares A, He L, Bergeron A, et al
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
Blood. 2019 May 10. pii: blood.2018862383. doi: 10.1182/blood.2018862383.
PubMed Abstract available

TAN SH, Leong WZ, Ngoc PCT, Tan TK, et al
The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.
Blood. 2019 May 10. pii: blood.2018874503. doi: 10.1182/blood.2018874503.
PubMed Abstract available

SLUPSKY JR
Ibrutinib is safer than we think.
Blood. 2019;133:2006-2007.
PubMed

WENDTNER CM
Ibrutinib: the home run for cure in CLL?
Blood. 2019;133:2003-2004.
PubMed

BYRD JC, Hillmen P, O'Brien S, Barrientos JC, et al
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood. 2019;133:2031-2042.
PubMed Abstract available

April 2019

DERRIEUX C, Tarfi S
Azurophilic granular blasts are not always part of myeloid lineage: an atypical case of BCP acute lymphoblastic leukemia.
Blood. 2019;133:1919.
PubMed

BJORKHOLM M, Edgren G, Dickman PW
Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and USA.
Blood. 2019 Apr 25. pii: blood.2019001168. doi: 10.1182/blood.2019001168.
PubMed

ROBERTS AW, Ma S, Kipps TJ, Coutre SE, et al
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood. 2019 Apr 25. pii: blood.2018882555. doi: 10.1182/blood.2018882555.
PubMed Abstract available

SCHEFFOLD A, Jebaraj BMC, Tausch E, Bloehdorn J, et al
IGF1R as druggable target mediating PI3K-delta inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Blood. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029.
PubMed Abstract available

PLESA A, Sujobert P
Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.
Blood. 2019;133:1789.
PubMed

TROWBRIDGE JJ
Context-specific tumor suppression by PHF6.
Blood. 2019;133:1698-1700.
PubMed

FORERO-TORRES A, Ramchandren R, Yacoub A, Wertheim MS, et al
Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies.
Blood. 2019;133:1742-1752.
PubMed Abstract available

CURRAN E, Stock W
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Blood. 2019;133:1715-1719.
PubMed Abstract available

JUTZI JS, Basu T, Pellmann M, Kaiser S, et al
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Blood. 2019;133:1766-1777.
PubMed Abstract available

YIN M, Chung YJ, Lindsley RC, Walker RL, et al
Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.
Blood. 2019 Apr 16. pii: blood.2018864173. doi: 10.1182/blood.2018864173.
PubMed Abstract available

ZHAN Y, Teruya-Feldstein J
Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL.
Blood. 2019;133:1695.
PubMed

HAY KA, Gauthier J, Hirayama AV, Voutsinas JM, et al
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Blood. 2019;133:1652-1663.
PubMed Abstract available

DOUGLAS SPM, Siipola P, Kovanen P, Pyorala M, et al
ERCC6L2 defines a novel entity within inherited acute myeloid leukemia.
Blood. 2019 Apr 1. pii: blood-2019-01-896233. doi: 10.1182/blood-2019-01-896233.
PubMed

NAKAMURA S, Yokoyama K, Shimizu E, Yusa N, et al
Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690.
PubMed Abstract available

March 2019

GHIA EM, Rassenti LZ, Neuberg DS, Blanco A, et al
Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.
Blood. 2019 Mar 28. pii: blood-2018-09-873695. doi: 10.1182/blood-2018-09-873695
PubMed Abstract available

LEVIS M
Arsenic and old FLT3.
Blood. 2019;133:1392-1393.
PubMed

WEI AH
Maintenance therapy for AML: are we there yet?
Blood. 2019;133:1390-1392.
PubMed

GOHIL SH, Wu CJ
Dissecting CLL through high-dimensional single-cell technologies.
Blood. 2019;133:1446-1456.
PubMed Abstract available

ESNAULT C, Rahme R, Rice KL, Berthier C, et al
FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
Blood. 2019;133:1495-1506.
PubMed Abstract available

GOLAY J, Valgardsdottir R, Musaraj G, Giupponi D, et al
Human neutrophils express low levels of FcgammaRIIIA, which plays a role in PMN activation.
Blood. 2019;133:1395-1405.
PubMed Abstract available

HULS G, Chitu DA, Havelange V, Jongen-Lavrencic M, et al
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Blood. 2019;133:1457-1464.
PubMed Abstract available

HIJIYA N, Suttorp M
How I Treat Chronic Myeloid Leukemia in Children and Adolescents.
Blood. 2019 Mar 27. pii: blood.2018882233. doi: 10.1182/blood.2018882233.
PubMed Abstract available

SARASIN A, Quentin S, Droin N, Sahbatou M, et al
Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.
Blood. 2019 Mar 26. pii: blood-2019-01-895698. doi: 10.1182/blood-2019-01-895698
PubMed

CARGO C, Cullen M, Taylor J, Short M, et al
The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
Blood. 2019;133:1325-1334.
PubMed Abstract available

ZEISER R, Vago L
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.
Blood. 2019;133:1290-1297.
PubMed Abstract available

LIU H
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged.
Blood. 2019;133:1265.
PubMed

FRANCISCHETTI IMB, Calvo KR
Hairy cell leukemia coexistent with chronic lymphocytic leukemia.
Blood. 2019;133:1264.
PubMed

ABRUZZO LV
Intricacies of CLL cytogenetic complexity.
Blood. 2019;133:1168-1170.
PubMed

BORDEN KLB
CDK9 and mTOR: trading places.
Blood. 2019;133:1167-1168.
PubMed

FLINN IW, Gribben JG, Dyer MJS, Wierda W, et al
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood. 2019 Mar 12. pii: blood-2019-01-896290. doi: 10.1182/blood-2019-01-896290
PubMed Abstract available

HAFERLACH T, Meggendorfer M
More than a fusion gene: the RUNX1-RUNX1T1 AML.
Blood. 2019;133:1006-1007.
PubMed

BYRD JC
Targeting CD20 takes the backseat in CLL.
Blood. 2019;133:1003-1004.
PubMed

MERKENSCHLAGER J, Eksmond U, Danelli L, Attig J, et al
MHC class II cell-autonomously regulates self-renewal and differentiation of normal and malignant B cells.
Blood. 2019;133:1108-1118.
PubMed Abstract available

PRONK E, Raaijmakers MHGP
The mesenchymal niche in MDS.
Blood. 2019;133:1031-1038.
PubMed Abstract available

TANAKA TN, Bejar R
MDS overlap disorders and diagnostic boundaries.
Blood. 2019;133:1086-1095.
PubMed Abstract available

OGAWA S
Genetics of MDS.
Blood. 2019;133:1049-1059.
PubMed Abstract available

February 2019

BROWN JR, O'Brien S, Kingsley CD, Eradat H, et al
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Blood. 2019;133:990-992.
PubMed

MORANDE PE, Sivina M, Uriepero A, Seija N, et al
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
Blood. 2019 Feb 27. pii: blood-2018-09-876292. doi: 10.1182/blood-2018-09-876292
PubMed Abstract available

SANZ MA, Fenaux P, Tallman MS, Estey EH, et al
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980
PubMed Abstract available

KAUFMANN KB, Garcia-Prat L, Liu Q, Ng SWK, et al
A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
Blood. 2019 Feb 22. pii: blood-2018-10-881441. doi: 10.1182/blood-2018-10-881441
PubMed Abstract available

SANCHEZ-MARTINEZ D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H, et al
Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Blood. 2019 Feb 22. pii: blood-2018-10-882944. doi: 10.1182/blood-2018-10-882944
PubMed Abstract available

ROSSI D
FBXW7 is a biologically validated cancer driver gene for CLL.
Blood. 2019;133:774-776.
PubMed

CLOSE V, Close W, Kugler SJ, Reichenzeller M, et al
FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.
Blood. 2019;133:830-839.
PubMed Abstract available

SCHMIEGELOW K
Yet another susceptibility variant for ALL: what's next?
Blood. 2019;133:628-629.
PubMed

BULLINGER L
IDH2 inhibition: another piece to the puzzle.
Blood. 2019;133:625-626.
PubMed

STERNER RM, Sakemura R, Cox MJ, Yang N, et al
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Blood. 2019;133:697-709.
PubMed Abstract available

MCRAE HM, Garnham AL, Hu Y, Witkowski MT, et al
PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.
Blood. 2019 Feb 12. pii: blood-2018-07-860726. doi: 10.1182/blood-2018-07-860726
PubMed Abstract available

SMITH CC
Roman warfare: targeting of support cells in AML.
Blood. 2019;133:506-507.
PubMed

January 2019

STEPHENS DM
Highs and lows of minimal residual disease in CLL.
Blood. 2019;133:386-388.
PubMed

LANGERAK AW, Ritgen M, Goede V, Robrecht S, et al
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Blood. 2019;133:494-497.
PubMed

NIEMEYER CM, Flotho C
Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Blood. 2019 Jan 22. pii: blood-2018-11-844688. doi: 10.1182/blood-2018-11-844688
PubMed Abstract available

STOCK W, Luger SM, Advani AS, Yin J, et al
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961
PubMed Abstract available

HALLNER A, Bernson E, Hussein BA, Sander FE, et al
The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Blood. 2019 Jan 15. pii: blood-2018-09-874990. doi: 10.1182/blood-2018-09-874990
PubMed Abstract available

STEPHENS DM, Byrd JC
How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Blood. 2019 Jan 14. pii: blood-2018-11-846808. doi: 10.1182/blood-2018-11-846808
PubMed Abstract available

XIE W, Xu J
Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia.
Blood. 2019;133:182.
PubMed

TORUNER GA, Thakral B
Relapsed NPM1 mutated acute myeloid leukemia with PDGFRA rearrangement.
Blood. 2019;133:181.
PubMed

SARRAF YAZDY M, Mato AR, Cheson BD
Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
Blood. 2019;133:121-129.
PubMed Abstract available

CHRISTEN F, Hoyer K, Yoshida K, Hou HA, et al
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Blood. 2019 Jan 4. pii: blood-2018-05-852822. doi: 10.1182/blood-2018-05-852822.
PubMed Abstract available

MICHAELIS LC
Venetoclax in AML: aiming for "just right".
Blood. 2019;133:3-4.
PubMed

BALIAKAS P, Jeromin S, Iskas M, Puiggros A, et al
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact.
Blood. 2019 Jan 2. pii: blood-2018-09-873083. doi: 10.1182/blood-2018-09-873083.
PubMed Abstract available

December 2018

BEAUCHAMP EM, Abedin SM, Radecki SG, Fischietti M, et al
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Blood. 2018 Dec 26. pii: blood-2018-08-870089. doi: 10.1182/blood-2018-08-870089
PubMed Abstract available

SCHLENK RF, Weber D, Fiedler W, Salih HR, et al
Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Blood. 2018 Dec 18. pii: blood-2018-08-869453. doi: 10.1182/blood-2018-08-869453
PubMed Abstract available

BILICH T, Nelde A, Bichmann L, Roerden M, et al
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Blood. 2018 Dec 10. pii: blood-2018-07-866830. doi: 10.1182/blood-2018-07-866830
PubMed Abstract available

BURGER JA, Sivina M, Jain N, Kim E, et al
Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood. 2018 Dec 7. pii: blood-2018-10-879429. doi: 10.1182/blood-2018-10-879429.
PubMed Abstract available

PASSET M, Boissel N, Sigaux F, Saillard C, et al
PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.
Blood. 2018 Dec 3. pii: blood-2018-10-882142. doi: 10.1182/blood-2018-10-882142.
PubMed

QIAN M, Xu H, Perez-Andreu V, Roberts KG, et al
Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics.
Blood. 2018 Dec 3. pii: blood-2018-07-862946. doi: 10.1182/blood-2018-07-862946.
PubMed Abstract available

STEIN EM, DiNardo CD, Fathi AT, Pollyea DA, et al
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood. 2018 Dec 3. pii: blood-2018-08-869008. doi: 10.1182/blood-2018-08-869008.
PubMed Abstract available

November 2018

KLAIRMONT MM, Choi JK
Mixed-phenotype acute leukemia, T/megakaryoblastic.
Blood. 2018;132:2418.
PubMed

NGUYEN TD, Shaid S, Vakhrusheva O, Koschade SE, et al
Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.
Blood. 2018 Nov 29. pii: blood-2018-02-833475. doi: 10.1182/blood-2018-02-833475
PubMed Abstract available

JIANG W, Lee SH
Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
Blood. 2018;132:2314.
PubMed

BROWN P, Pieters R, Biondi A
How I treat infant leukemia.
Blood. 2018 Nov 20. pii: blood-2018-04-785980. doi: 10.1182/blood-2018-04-785980
PubMed Abstract available

RAVANDI F
How I treat Philadelphia chromosome positive acute lymphoblastic leukemia.
Blood. 2018 Nov 15. pii: blood-2018-08-832105. doi: 10.1182/blood-2018-08-832105
PubMed Abstract available

EDWARDS DK 5TH, Watanabe-Smith K, Rofelty A, Damnernsawad A, et al
CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
Blood. 2018 Nov 13. pii: blood-2018-03-838946. doi: 10.1182/blood-2018-03-838946
PubMed Abstract available

LEBECQUE B, Lechevalier N
B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia.
Blood. 2018;132:2107.
PubMed

ABDUL-AZIZ AM, Sun Y, Hellmich C, Marlein CR, et al
Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment.
Blood. 2018 Nov 6. pii: blood-2018-04-845420. doi: 10.1182/blood-2018-04-845420.
PubMed Abstract available

October 2018

DINARDO CD, Pratz K, Pullarkat V, Jonas BA, et al
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood. 2018 Oct 25. pii: blood-2018-08-868752. doi: 10.1182/blood-2018-08-868752
PubMed Abstract available

BERTAINA A, Zecca M, Buldini B, Sacchi N, et al
Unrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemia.
Blood. 2018 Oct 22. pii: blood-2018-07-861575. doi: 10.1182/blood-2018-07-861575
PubMed Abstract available

ZHANG J, Zhang Y, Zhang M, Liu C, et al
FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia.
Blood. 2018 Oct 3. pii: blood-2018-04-845628. doi: 10.1182/blood-2018-04-845628.
PubMed

HERRMANN M, Krupka C, Deiser K, Brauchle B, et al
Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood. 2018 Oct 1. pii: blood-2018-05-849802. doi: 10.1182/blood-2018-05-849802.
PubMed Abstract available

September 2018

CHEN LS, Bose P, Cruz ND, Jiang Y, et al
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Blood. 2018 Sep 25. pii: blood-2018-06-860593. doi: 10.1182/blood-2018-06-860593
PubMed Abstract available

BALATTI V, Tomasello L, Rassenti LZ, Veneziano D, et al
MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
Blood. 2018 Sep 21. pii: blood-2018-04-845115. doi: 10.1182/blood-2018-04-845115
PubMed Abstract available

BOSMA M, Bartels M
Hairy cell leukemia in a child?!
Blood. 2018;132:1216.
PubMed

KATSURAGI T, Tsukada J
Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
Blood. 2018;132:1086.
PubMed

BRETONES G, Alvarez MG, Arango JR, Rodriguez D, et al
Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.
Blood. 2018 Sep 4. pii: blood-2017-09-804401. doi: 10.1182/blood-2017-09-804401.
PubMed Abstract available

August 2018

ALSADEQ A, Lenk L, Vadakumchery A, Cousins A, et al
IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.
Blood. 2018 Aug 28. pii: blood-2018-04-844209. doi: 10.1182/blood-2018-04-844209
PubMed

MEDEIROS BC
Non-zero-sum game of transfusions: EOL in leukemia.
Blood. 2018;132:676-678.
PubMed

ROGERS KA, Huang Y, Ruppert AS, Awan FT, et al
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Blood. 2018 Aug 15. pii: blood-2018-05-853564. doi: 10.1182/blood-2018-05-853564
PubMed Abstract available

KIM T, Moon JH, Ahn JS, Kim YK, et al
Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia.
Blood. 2018 Aug 14. pii: blood-2018-04-848028. doi: 10.1182/blood-2018-04-848028
PubMed Abstract available

FERGUSON D, Kovach AE
Rasburicase-induced hemolytic anemia in previously undiagnosed G6PD deficiency.
Blood. 2018;132:673.
PubMed

July 2018

PIKMAN Y, Stegmaier K
Targeted therapy for fusion-driven high-risk acute leukemia.
Blood. 2018 Jul 26. pii: blood-2018-04-784157. doi: 10.1182/blood-2018-04-784157
PubMed Abstract available

RICHARDSON AI, Li W
Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia.
Blood. 2018;132:457.
PubMed

LI W, Chastain K
NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia.
Blood. 2018;132:456.
PubMed

Ambiguous lineage leukemia treatment.
Blood. 2018;132:343.
PubMed

DREGER P, Ghia P, Schetelig J, van Gelder M, et al
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008
PubMed Abstract available

SUD A, Chattopadhyay S, Thomsen H, Sundquist K, et al
Familial risks of primary myeloid leukemia, myelodysplasia and myeloproliferative neoplasms.
Blood. 2018 Jul 10. pii: blood-2018-06-858597. doi: 10.1182/blood-2018-06-858597
PubMed

THAKRAL B, Wang SA
T-cell prolymphocytic leukemia negative for surface CD3 and CD45.
Blood. 2018;132:111.
PubMed

June 2018

SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991
PubMed

O'DWYER K, Freyer DR, Horan JT
Treatment strategies for adolescent and young adult patients with acute myeloid leukemia.
Blood. 2018 Jun 12. pii: blood-2017-12-778472. doi: 10.1182/blood-2017-12-778472
PubMed Abstract available

BOISSEL N, Baruchel A
Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
Blood. 2018 Jun 12. pii: blood-2018-02-778530. doi: 10.1182/blood-2018-02-778530
PubMed Abstract available

ROBERTS KG, Janke LJ, Zhao Y, Seth A, et al
ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
Blood. 2018 Jun 7. pii: blood-2018-05-849554. doi: 10.1182/blood-2018-05-849554.
PubMed

May 2018

ALDOSS I, Song JY
Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.
Blood. 2018;131:2507.
PubMed

LEBLANC TW, Egan PC, Olszewski AJ
Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.
Blood. 2018 May 30. pii: blood-2018-03-842575. doi: 10.1182/blood-2018-03-842575
PubMed Abstract available

MELO-CARDENAS J, Xu Y, Wei J, Tan C, et al
USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism.
Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760
PubMed Abstract available

PATEL SS, Dorfman DM
Leukemic-phase progression of aleukemic mast cell leukemia.
Blood. 2018;131:2406.
PubMed

TESTI AM, Pession A, Diverio D, Grimwade D, et al
Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.
Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528
PubMed Abstract available

MAIFREDE S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood. 2018 May 21. pii: blood-2018-02-834895. doi: 10.1182/blood-2018-02-834895
PubMed Abstract available

CLOT G, Jares P, Gine E, Navarro A, et al
A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
PubMed Abstract available

LUO H, Wang F, Zha J, Li H, et al
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
Blood. 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319
PubMed Abstract available

OLAIYA OO, Li W
Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia.
Blood. 2018;131:2178.
PubMed

ROBINSON HR, Qi J, Cook EM, Nichols C, et al
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Blood. 2018 May 9. pii: blood-2018-02-830992. doi: 10.1182/blood-2018-02-830992.
PubMed Abstract available

TOPP MS, Zimmerman Z, Cannell P, Dombret H, et al
Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Blood. 2018 May 8. pii: blood-2017-09-804658. doi: 10.1182/blood-2017-09-804658.
PubMed Abstract available

ZHU HH, Liu YR
Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia.
Blood. 2018 May 4. pii: blood-2018-02-834051. doi: 10.1182/blood-2018-02-834051.
PubMed

STEIN EM, Garcia-Manero G, Rizzieri DA, Tibes R, et al
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood. 2018 May 3. pii: blood-2017-12-818948. doi: 10.1182/blood-2017-12-818948.
PubMed Abstract available

HRUSAK O, De Haas V, Stancikova J, Vakrmanova B, et al
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363.
PubMed Abstract available

April 2018

LI S, Xu J
Plasma cell leukemia presenting as "lymphocytosis".
Blood. 2018;131:1994.
PubMed

YANG J, LeBlanc FR, Dighe SA, Hamele CE, et al
TRAIL mediates and sustains constitutive NF-kappaB activation in LGL leukemia.
Blood. 2018 Apr 26. pii: blood-2017-09-808816. doi: 10.1182/blood-2017-09-808816
PubMed Abstract available

MCKENNA MK, Noothi SK, Alhakeem SS, Oben KZ, et al
Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
Blood. 2018 Apr 25. pii: blood-2017-10-813931. doi: 10.1182/blood-2017-10-813931
PubMed Abstract available

ITZYKSON R, Duployez N, Fasan A, Decool G, et al
Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.
Blood. 2018 Apr 24. pii: blood-2018-03-837781. doi: 10.1182/blood-2018-03-837781
PubMed Abstract available

HASAN MK, Yu J, Widhopf GF 2nd, Rassenti LZ, et al
Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
Blood. 2018 Apr 20. pii: blood-2017-12-819383. doi: 10.1182/blood-2017-12-819383
PubMed Abstract available

KLEINSTERN G, Camp NJ, Goldin LR, Vachon CM, et al
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
Blood. 2018 Apr 19. pii: blood-2017-11-814608. doi: 10.1182/blood-2017-11-814608
PubMed Abstract available

HEERY DM
A fellowship of Ring1 maintains AML stem cells.
Blood. 2018;131:1771-1773.
PubMed

LAETSCH TW, Maude SL, Milone MC, Davis KL, et al
False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
Blood. 2018 Apr 18. pii: blood-2017-12-822940. doi: 10.1182/blood-2017-12-822940
PubMed

PUENTE XS, Jares P, Campo E
Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
PubMed Abstract available

RANK CU, Toft N, Tuckuviene R, Grell K, et al
Thromboembolism in Acute Lymphoblastic Leukemia: Results of NOPHO ALL2008 Protocol Treatment in Patients 1-45 Years.
Blood. 2018 Apr 16. pii: blood-2018-01-827949. doi: 10.1182/blood-2018-01-827949
PubMed Abstract available

JIANG X, Zhou D
ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
Blood. 2018;131:1764.
PubMed

WANG F, Demir S, Gehringer F, Osswald CD, et al
Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
PubMed Abstract available

KRAUSE DS
Et tu, E2F1? The assassins of CML stem cells.
Blood. 2018;131:1499-1500.
PubMed

STATLER A, Othus M, Erba HP, Chauncey TR, et al
Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
PubMed Abstract available

March 2018

CORTES JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, et al
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086
PubMed Abstract available

PAIETTA E
Consensus on MRD in AML?
Blood. 2018;131:1265-1266.
PubMed

SCHUURHUIS GJ, Heuser M, Freeman S, Bene MC, et al
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood. 2018;131:1275-1291.
PubMed Abstract available

WOOD B, Wu D, Crossley B, Dai Y, et al
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Blood. 2018;131:1350-1359.
PubMed Abstract available

RUIZ S, Chen YH
Acute myeloid leukemia with coexistence of t(9;22) and inv(16).
Blood. 2018;131:1263.
PubMed

HALLEK M, Cheson BD, Catovsky D, Caligaris-Cappio F, et al
Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
Blood. 2018 Mar 14. pii: blood-2017-09-806398. doi: 10.1182/blood-2017-09-806398
PubMed Abstract available

YAMATO G, Shiba N, Yoshida K, Hara Y, et al
RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
Blood. 2018 Mar 14. pii: blood-2017-11-814442. doi: 10.1182/blood-2017-11-814442
PubMed

SMITH M, Zakrzewski J, James S, Sadelain M, et al
Posttransplant chimeric antigen receptor therapy.
Blood. 2018;131:1045-1052.
PubMed Abstract available

SOIFFER RJ, Davids MS, Chen YB
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.
Blood. 2018;131:1073-1080.
PubMed Abstract available

ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Blood. 2018;131:1094-1105.
PubMed Abstract available

SHOMALI W, Gotlib J
Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
Blood. 2018;131:1036.
PubMed

WYNNE J, Stock W
"Dar"-ing to target CD38 in T-ALL.
Blood. 2018;131:948-949.
PubMed

THOMPSON PA
MRD negativity as a surrogate for PFS in CLL?
Blood. 2018;131:943-944.
PubMed

DIMIER N, Delmar P, Ward C, Morariu-Zamfir R, et al
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood. 2018;131:955-962.
PubMed Abstract available

February 2018

KREITMAN RJ, Tallman MS, Robak T, Coutre S, et al
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
Blood. 2018 Feb 27. pii: blood-2017-09-803072. doi: 10.1182/blood-2017-09-803072
PubMed Abstract available

DUARTE D, Hawkins ED, Lo Celso C
The interplay of leukemia cells and the bone marrow microenvironment.
Blood. 2018 Feb 27. pii: blood-2017-12-784132. doi: 10.1182/blood-2017-12-784132
PubMed Abstract available

LIU T, Wen L, Yuan H, Wang Y, et al
Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
Blood. 2018 Feb 27. pii: blood-2017-11-818716. doi: 10.1182/blood-2017-11-818716
PubMed

SCHLIFFKE S, Buhs S, Bolz S, Gerull H, et al
The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
Blood. 2018 Feb 23. pii: blood-2017-06-788166. doi: 10.1182/blood-2017-06-788166
PubMed

JAITLY V, Wang W
B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
Blood. 2018;131:941.
PubMed

SIREF A, Huang Q
Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
Blood. 2018;131:940.
PubMed

GALLIPOLI P, Giotopoulos G, Tzelepis K, Costa ASH, et al
Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
Blood. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035
PubMed Abstract available

SCHAFER D, Olsen M, Lahnemann D, Stanulla M, et al
Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.
Blood. 2018;131:821-826.
PubMed

CARAFFINI V, Perfler B, Berg JL, Uhl B, et al
Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
Blood. 2018;131:826-830.
PubMed

WIERZ M, Pierson S, Guyonnet L, Viry E, et al
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267
PubMed

BHAGWAT AS, Lu B, Vakoc CR
Enhancer dysfunction in leukemia.
Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
PubMed Abstract available

NAKADA D
ENLightening YEATS in antagonizing polycomb repression.
Blood. 2018;131:591.
PubMed

HETZNER K, Garcia-Cuellar MP, Buttner C, Slany RK, et al
The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
Blood. 2018;131:662-673.
PubMed Abstract available

VOISSET E, Moravcsik E, Stratford EW, Jaye A, et al
Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
Blood. 2018;131:636-648.
PubMed Abstract available

GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Blood. 2018;131:611-620.
PubMed Abstract available

ZHANG Y, Gao Y, Zhang H, Zhang J, et al
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
PubMed Abstract available

YUN S, Zhang L, Patel MR, Knepper TC, et al
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.
PubMed

MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
Integrated molecular profiling of juvenile myelomonocytic leukemia.
Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
PubMed Abstract available

O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
PubMed Abstract available

LAZAREVIC V, Orsmark-Pietras C, Lilljebjorn H, Pettersson L, et al
Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.
Blood. 2018;131:577-581.
PubMed

January 2018

DINMOHAMED AG, Posthuma EFM, Visser O, Kater AP, et al
Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands.
Blood. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381
PubMed

SHIMA H, Takamatsu-Ichihara E, Shino M, Yamagata K, et al
Ring1A and Ring 1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells.
Blood. 2018 Jan 25. pii: blood-2017-05-787226. doi: 10.1182/blood-2017-05-787226
PubMed Abstract available

TAKAHASHI K, Hu B, Wang F, Yan Y, et al
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
Blood. 2018 Jan 22. pii: blood-2017-11-817296. doi: 10.1182/blood-2017-11-817296
PubMed Abstract available

GOKBUGET N, Dombret H, Bonifacio M, Reichle A, et al
Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
Blood. 2018 Jan 22. pii: blood-2017-08-798322. doi: 10.1182/blood-2017-08-798322
PubMed Abstract available

HANDGRETINGER R, Schilbach K
The potential role of gammadelta T cells after allogeneic HCT for leukemia.
Blood. 2018 Jan 22. pii: blood-2017-08-752162. doi: 10.1182/blood-2017-08-752162
PubMed Abstract available

COOLEY S, Parham P, Miller JS
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Blood. 2018 Jan 22. pii: blood-2017-08-752170. doi: 10.1182/blood-2017-08-752170
PubMed Abstract available

GUTJAHR JC, Szenes E, Tschech L, Asslaber D, et al
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Blood. 2018 Jan 19. pii: blood-2017-08-802462. doi: 10.1182/blood-2017-08-802462
PubMed Abstract available

PFEIFER H, Raum K, Markovic S, Nowak V, et al
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
Blood. 2018 Jan 18. pii: blood-2017-07-796862. doi: 10.1182/blood-2017-07-796862
PubMed Abstract available

SUN W, Triche T Jr., Malvar J, Gaynon P, et al
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.
Blood. 2018 Jan 16. pii: blood-2017-09-803809. doi: 10.1182/blood-2017-09-803809
PubMed Abstract available

JANOVSKA P, Verner J, Kohoutek J, Bryjova L, et al
Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.
Blood. 2018 Jan 9. pii: blood-2017-05-786947. doi: 10.1182/blood-2017-05-786947.
PubMed Abstract available

BRIDE KL, Vincent TL, Im SY, Aplenc R, et al
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).
Blood. 2018 Jan 5. pii: blood-2017-07-794214. doi: 10.1182/blood-2017-07-794214.
PubMed Abstract available

COUTRE S, Choi M, Furman RR, Eradat H, et al
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood. 2018 Jan 5. pii: blood-2017-06-788133. doi: 10.1182/blood-2017-06-788133.
PubMed Abstract available

LOCKE FL, Anasetti C
Off-the-shelf TCR for graft-versus-leukemia without GVHD.
Blood. 2018;131:5-7.
PubMed

MILNE TA
LEDGF: a leukemia-specific target.
Blood. 2018;131:4-5.
PubMed

AULETTA JJ
AML: exposed and exploited?
Blood. 2018;131:8-10.
PubMed

EL ASHKAR S, Schwaller J, Pieters T, Goossens S, et al
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
Blood. 2018;131:95-107.
PubMed Abstract available

HILL JA, Li D, Hay KA, Green ML, et al
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Blood. 2018;131:121-130.
PubMed Abstract available

December 2017

GROCKOWIAK E, Laperrousaz B, Jeanpierre S, Voeltzel T, et al
Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
Blood. 2017;130:2860-2871.
PubMed Abstract available

SHIOZAWA Y, Malcovati L, Galli A, Pellagatti A, et al
Gene expression and risk of leukemic transformation in myelodysplasia.
Blood. 2017;130:2642-2653.
PubMed Abstract available

PRATS-MARTIN C, Morales-Camacho RM
Circulating hypergranular neoplastic cells: not always leukemic promyelocytes.
Blood. 2017;130:2689.
PubMed

YAO L, Wen L, Wang N, Liu T, et al
Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA.
Blood. 2017 Dec 13. pii: blood-2017-09-807370. doi: 10.1182/blood-2017-09-807370
PubMed

RAIKAR SS, Park SI, Leong T, Jaye DL, et al
Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.
PubMed

WEI AH, Tiong IS
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Blood. 2017;130:2469-2474.
PubMed Abstract available

BOSE P, Konopleva MY
T-PLL: another check on the venetoclax list?
Blood. 2017;130:2447-2448.
PubMed

OBSTFELD AE, Frey NV, Mansfield K, Lacey SF, et al
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
Blood. 2017;130:2569-2572.
PubMed

STEIN EM, Walter RB, Erba HP, Fathi AT, et al
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML).
Blood. 2017 Dec 1. pii: blood-2017-06-789800. doi: 10.1182/blood-2017-06-789800.
PubMed Abstract available

November 2017

COOPER JN, Young NS
Clonality in context: hematopoietic clones in their marrow environment.
Blood. 2017;130:2363-2372.
PubMed Abstract available

ZHEN T, Kwon EM, Zhao L, Hsu J, et al
Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.
Blood. 2017;130:2431-2442.
PubMed Abstract available

RASHIDI A, Gilles S
The unused iron.
Blood. 2017;130:2445.
PubMed

STRAUBE J, Ling VY, Hill GR, Lane SW, et al
The impact of age, NPM1(mut) and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia.
Blood. 2017 Nov 28. pii: blood-2017-09-807438. doi: 10.1182/blood-2017-09-807438
PubMed

JOHNSRUD AJ, Pina-Oviedo S
Carcinocythemia (carcinoma cell leukemia).
Blood. 2017;130:2357.
PubMed

CHAI-ADISAKSOPHA C, Brown JR
FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
Blood. 2017;130:2278-2282.
PubMed Abstract available

THAKRAL B, Konoplev S
"Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
Blood. 2017;130:2358.
PubMed

CRANE GM, Perkins AS
Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
Blood. 2017;130:2233.
PubMed

QUESADA AE, Konoplev S
Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
Blood. 2017;130:2151.
PubMed

HU Z, Konoplev S
Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia.
Blood. 2017;130:2150.
PubMed

ISSA GC, Kantarjian HM, Gonzalez GN, Borthakur G, et al
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
Blood. 2017;130:2084-2091.
PubMed Abstract available

HEHLMANN R
Prognostic relevance of CCAs/Ph(-) in CML settled.
Blood. 2017;130:2046-2047.
PubMed

LOCATELLI F, Valsecchi MG, Moricke A, Zimmermann M, et al
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
Blood. 2017;130:2146-2149.
PubMed

SERAFIN V, Capuzzo G, Milani G, Minuzzo SA, et al
Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Blood. 2017 Nov 3. pii: blood-2017-05-784603. doi: 10.1182/blood-2017-05-784603.
PubMed Abstract available

TAWARA I, Kageyama S, Miyahara Y, Fujiwara H, et al
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Blood. 2017;130:1985-1994.
PubMed Abstract available

October 2017

MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
Chronic lymphocytic leukemia international prognostic index (CLL-IPI): a systematic review and meta-analysis.
Blood. 2017 Oct 30. pii: blood-2017-09-806034. doi: 10.1182/blood-2017-09-806034
PubMed

KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
PubMed Abstract available

FALINI B, Sportoletti P
A scale of "bad" co-mutations in NPM1-driven AML.
Blood. 2017;130:1877-1879.
PubMed

BOUVIER S, Martin M
Atypical monoblasts with micronuclei.
Blood. 2017;130:1958.
PubMed

GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
PubMed Abstract available

DOSSA RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, et al
Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
Blood. 2017 Oct 19. pii: blood-2017-07-791608. doi: 10.1182/blood-2017-07-791608
PubMed Abstract available

PETIT A, Trinquand A, Chevret S, Ballerini P, et al
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic Leukemia.
Blood. 2017 Oct 19. pii: blood-2017-04-778829. doi: 10.1182/blood-2017-04-778829
PubMed Abstract available

TIAO G, Improgo MR, Tausch E, Fernandes SM, et al
Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.
Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128
PubMed

HARANKHEDKAR S, Gupta R
MPO-negative inclusions and Auer rod-like structures in a case of acute myeloid leukemia with t(8;21).
Blood. 2017;130:1869.
PubMed

RUTHERFORD SC, Leonard JP
Lymphoma "benchmark" or "bench-smudge"?
Blood. 2017;130:1778-1779.
PubMed

ODA SK, Daman AW, Garcia NM, Wagener F, et al
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.
Blood. 2017 Oct 17. pii: blood-2017-04-777052. doi: 10.1182/blood-2017-04-777052
PubMed Abstract available

SANDA T
RUNX1 in T-ALL: tumor suppressive or oncogenic?
Blood. 2017;130:1686-1688.
PubMed

XU Z
AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis.
Blood. 2017;130:1775.
PubMed

APPELBAUM FR, Bernstein ID
Gemtuzumab ozogamicin for acute myeloid leukemia.
Blood. 2017 Oct 11. pii: blood-2017-09-797712. doi: 10.1182/blood-2017-09-797712
PubMed Abstract available

MAR BG, Chu SH, Kahn JD, Krivstov AV, et al
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
Blood. 2017 Oct 10. pii: blood-2017-03-775569. doi: 10.1182/blood-2017-03-775569
PubMed Abstract available

WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017;130:1620-1627.
PubMed Abstract available

BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
Blood. 2017;130:1628-1638.
PubMed Abstract available

MARLEIN CR, Zaitseva L, Piddock RE, Robinson SD, et al
NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.
Blood. 2017;130:1649-1660.
PubMed Abstract available

WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
PubMed Abstract available

TASIAN SK, Loh ML, Hunger SP
Philadelphia chromosome-like acute lymphoblastic leukemia.
Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
PubMed Abstract available

September 2017

THAKRAL B, Wang SA
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Blood. 2017;130:1600.
PubMed

KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
Blood. 2017;130:1585-1596.
PubMed Abstract available

JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Blood. 2017;130:1514-1522.
PubMed Abstract available

ADVANI AS
"MOR" engineering of antibodies in ALL.
Blood. 2017;130:1487-1488.
PubMed

BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
PubMed Abstract available

MUELLER KT, Maude SL, Porter DL, Frey N, et al
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
PubMed Abstract available

SHEA TC
Are outcomes of allografts for CLL still relevant?
Blood. 2017;130:1393-1394.
PubMed

ZHENG L, Hu S
Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
Blood. 2017;130:1483.
PubMed

KRAMER I, Stilgenbauer S, Dietrich S, Bottcher S, et al
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
Blood. 2017;130:1477-1480.
PubMed

ZURLI V, Wimmer G, Cattaneo F, Candi V, et al
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Blood. 2017 Sep 20. pii: blood-2017-03-775858. doi: 10.1182/blood-2017-03-775858
PubMed Abstract available

WANG HY, Feldman AL
Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia.
Blood. 2017;130:1387.
PubMed

LIN S, Ptasinska A, Chen X, Shrestha M, et al
A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
Blood. 2017;130:1213-1222.
PubMed Abstract available

ASEMISSEN AM, Dierlamm J
The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
Blood. 2017;130:1274.
PubMed

AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
Blood. 2017;130:1270-1273.
PubMed

August 2017

BAZARBACHI A
CDK9 inhibition for ATL therapy.
Blood. 2017;130:1074-1075.
PubMed

LEHNERTZ B, Zhang YW, Boivin I, Mayotte N, et al
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.
Blood. 2017 Aug 30. pii: blood-2017-03-774653. doi: 10.1182/blood-2017-03-774653
PubMed Abstract available

DOVEY OM, Cooper JL, Mupo A, Grove CS, et al
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.
Blood. 2017 Aug 23. pii: blood-2017-01-760595. doi: 10.1182/blood-2017-01-760595
PubMed Abstract available

BRUNSON A, Keegan THM, Bang H, Mahajan A, et al
Increased risk of leukemia among sickle cell disease patients in California.
Blood. 2017 Aug 22. pii: blood-2017-05-783233. doi: 10.1182/blood-2017-05-783233
PubMed

ANGUILLE S, Van de Velde AL, Smits EL, Van Tendeloo VF, et al
Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia.
Blood. 2017 Aug 22. pii: blood-2017-04-780155. doi: 10.1182/blood-2017-04-780155
PubMed Abstract available

NAGEL I, Bartels M, Duell J, Oberg HH, et al
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.
Blood. 2017 Aug 21. pii: blood-2017-05-782888. doi: 10.1182/blood-2017-05-782888
PubMed Abstract available

ZHOU XY, Behdad A
Relapse of an acute leukemia of mixed lineage as an isolated orbital mass.
Blood. 2017;130:953.
PubMed

KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Blood. 2017;130:908-919.
PubMed Abstract available

MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Blood. 2017;130:946-948.
PubMed

DURHAM BH, Getta B, Dietrich S, Taylor J, et al
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
PubMed Abstract available

KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Blood. 2017;130:789-802.
PubMed Abstract available

WOUTERS BJ
Hitting the target in IDH2 mutant AML.
Blood. 2017;130:693-694.
PubMed

SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
Blood. 2017;130:832-835.
PubMed

WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Aug 9. pii: blood-2017-02-749101. doi: 10.1182/blood-2017-02-749101.
PubMed Abstract available

CHOI A, Illendula A, Pulikkan JA, Roderick JE, et al
RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia.
Blood. 2017 Aug 8. pii: blood-2017-03-775536. doi: 10.1182/blood-2017-03-775536.
PubMed Abstract available

LAFAGE-POCHITALOFF M, Baranger L, Hunault M, Cuccuini W, et al
Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
Blood. 2017 Aug 8. pii: blood-2017-05-783852. doi: 10.1182/blood-2017-05-783852.
PubMed Abstract available

MIZUKAWA B, O'Brien E, Moreira DC, Wunderlich M, et al
Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
Blood. 2017 Aug 4. pii: blood-2016-12-758458. doi: 10.1182/blood-2016-12-758458.
PubMed Abstract available

LILLJEBJORN H, Fioretos T
New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
Blood. 2017 Aug 4. pii: blood-2017-05-742643. doi: 10.1182/blood-2017-05-742643.
PubMed Abstract available

ARRANTO C, Tzankov A
Broken heart by T-prolymphocytic leukemia.
Blood. 2017;130:691.
PubMed

IZRAELI S, Eckert C
Targeted therapy of CNS leukemia?
Blood. 2017;130:562-563.
PubMed

CARTRON G, Watier H
Obinutuzumab: what is there to learn from clinical trials?
Blood. 2017;130:581-589.
PubMed Abstract available

July 2017

WALLACE JA, O'Connell RM
MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
Blood. 2017 Jul 27. pii: blood-2016-10-697698. doi: 10.1182/blood-2016-10-697698
PubMed Abstract available

GODLEY LA, Shimamura A
Genetic predisposition to hematologic malignancies: management and surveillance.
Blood. 2017;130:424-432.
PubMed Abstract available

YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Blood. 2017;130:397-407.
PubMed Abstract available

RAU RE
CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3.
Blood. 2017;130:385-386.
PubMed

DONG L, Zheng H, Qu CK
CCL3 is a key mediator for the leukemogenic effect of Ptpn11 activating mutations in the stem cell microenvironment.
Blood. 2017 Jul 27. pii: blood-2017-06-791103. doi: 10.1182/blood-2017-06-791103
PubMed

TOBOSO DG, Campos CB
Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32).
Blood. 2017;130:380.
PubMed

GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Blood. 2017;130:285-296.
PubMed Abstract available

AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Blood. 2017;130:297-309.
PubMed Abstract available

Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
Blood. 2017;130:232.
PubMed

THAKRAL B, Muzzafar T
Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
Blood. 2017;130:231.
PubMed

TALSMA CE, Boyer DF
Myeloid leukemia associated with Down syndrome.
Blood. 2017;130:230.
PubMed

AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Blood. 2017;130:156-166.
PubMed Abstract available

SAMPATH D
Targeting deubiquitinases in CLL.
Blood. 2017;130:100-101.
PubMed

PILLAI V, Maude SL
CART attack.
Blood. 2017;130:229.
PubMed

SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
PubMed Abstract available

CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121
PubMed

BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
Blood. 2017;130:86-88.
PubMed

KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
Blood. 2017;130:84-86.
PubMed

June 2017

QUESADA AE, Kanagal-Shamanna R
Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
Blood. 2017;129:3503.
PubMed

LEVIS M
Midostaurin approved for FLT3-mutated AML.
Blood. 2017;129:3403-3406.
PubMed Abstract available

CHAUDHRY P, Singh M, Triche TJ, Guzman M, et al
GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
Blood. 2017;129:3465-3475.
PubMed Abstract available

PAGEL JM
A Richter transformation PD-1 block party.
Blood. 2017;129:3397-3398.
PubMed

RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
Blood. 2017;129:3495-3498.
PubMed

MORIYAMA T, Yang YL, Nishii R, Ariffin H, et al
Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
Blood. 2017 Jun 28. pii: blood-2017-05-782383. doi: 10.1182/blood-2017-05-782383
PubMed Abstract available

NARITA T, Ishida T, Ito A, Masaki A, et al
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
PubMed Abstract available

BRIERLEY CK, Eyre TA
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
Blood. 2017;129:3396.
PubMed

ANDERSON MA, Tam C, Lew TE, Juneja S, et al
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Blood. 2017;129:3362-3370.
PubMed Abstract available

MALCOVATI L, Galli A, Travaglino E, Ambaglio I, et al
Clinical significance of somatic mutation in unexplained blood cytopenia.
Blood. 2017;129:3371-3378.
PubMed Abstract available

RESHMI SC, Harvey RC, Roberts KG, Stonerock E, et al
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Blood. 2017;129:3352-3361.
PubMed Abstract available

TOMIZAWA D, Kolb EA
Down syndrome and AML: where do we go from here?
Blood. 2017;129:3274-3275.
PubMed

SHAND JC
Looking up for AML in Down syndrome.
Blood. 2017;129:3273-3274.
PubMed

GRIBBEN JG
Restoring leukemia cell function from the inside out.
Blood. 2017;129:3137-3138.
PubMed

GOOSSENS S, Van Vlierberghe P
Novel oncogenic noncoding mutations in T-ALL.
Blood. 2017;129:3140-3142.
PubMed

GARRISON BS, Rybak AP, Beerman I, Heesters B, et al
ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
Blood. 2017 Jun 14. pii: blood-2016-09-738591. doi: 10.1182/blood-2016-09-738591
PubMed Abstract available

PROKOCIMER M, Molchadsky A, Rotter V
Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy.
Blood. 2017 Jun 12. pii: blood-2017-02-763086. doi: 10.1182/blood-2017-02-763086
PubMed Abstract available

PRIETO D, Sotelo N, Seija N, Sernbo S, et al
S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-kappaB activity during disease progression.
Blood. 2017 Jun 8. pii: blood-2017-02-769851. doi: 10.1182/blood-2017-02-769851.
PubMed Abstract available

WALLACE JA, Kagele DA, Eiring AM, Kim CN, et al
miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
Blood. 2017;129:3074-3086.
PubMed Abstract available

RASHIDI A, Courville EL
Double-heart sign.
Blood. 2017;129:3134.
PubMed

KATO I, Nishinaka Y, Nakamura M, Akarca AU, et al
Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.
Blood. 2017;129:3126-3129.
PubMed

STEIN EM, DiNardo CD, Pollyea DA, Fathi AT, et al
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.
Blood. 2017 Jun 6. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.
PubMed Abstract available

AMATANGELO MD, Quek L, Shih A, Stein EM, et al
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Blood. 2017 Jun 6. pii: blood-2017-04-779447. doi: 10.1182/blood-2017-04-779447.
PubMed Abstract available

LOCATELLI F, Merli P, Pagliara D, Li Pira G, et al
Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion.
Blood. 2017 Jun 6. pii: blood-2017-04-779769. doi: 10.1182/blood-2017-04-779769.
PubMed Abstract available

CHELONI G, Tanturli M, Tusa I, DeSouza NH, et al
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Blood. 2017 Jun 2. pii: blood-2016-10-745588. doi: 10.1182/blood-2016-10-745588.
PubMed Abstract available

SOLARY E, Itzykson R
How I treat chronic myelomonocytic leukemia.
Blood. 2017 Jun 1. pii: blood-2017-04-736421. doi: 10.1182/blood-2017-04-736421.
PubMed Abstract available

May 2017

MUNCH V, Trentin L, Herzig J, Demir S, et al
Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor.
Blood. 2017 May 26. pii: blood-2017-03-769315. doi: 10.1182/blood-2017-03-769315
PubMed Abstract available

MAN N, Tan Y, Sun XJ, Liu F, et al
Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
Blood. 2017;129:2782-2792.
PubMed Abstract available

HOVORKOVA L, Zaliova M, Venn NC, Bleckmann K, et al
Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
Blood. 2017;129:2771-2781.
PubMed Abstract available

HUNGER SP
CML in blast crisis: more common than we think?
Blood. 2017;129:2713-2714.
PubMed

WALTER HS, Jayne S, Rule SA, Cartron G, et al
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
Blood. 2017;129:2808-2810.
PubMed

KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
PubMed Abstract available

CHEN TL, Tran M, Lakshmanan A, Harrington BK, et al
NF-kappaB p50 (nfkb1) contributes to pathogenesis in the Emu-TCL1 mouse model of chronic lymphocytic leukemia.
Blood. 2017 May 17. pii: blood-2017-01-761130. doi: 10.1182/blood-2017-01-761130
PubMed

BARR PM, Brown JR, Hillmen P, O'Brien S, et al
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood. 2017;129:2612-2615.
PubMed Abstract available

VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
Blood. 2017;129:2636-2644.
PubMed Abstract available

LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
Blood. 2017;129:2657-2666.
PubMed Abstract available

WANG HY, Hodkoff A
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
Blood. 2017;129:2711.
PubMed

PINTON P
A mitochondrial drug to treat AML.
Blood. 2017;129:2597-2599.
PubMed

SMITH CC, Paguirigan A, Jeschke GR, Lin KC, et al
Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis.
Blood. 2017 May 10. pii: blood-2016-04-711820. doi: 10.1182/blood-2016-04-711820
PubMed Abstract available

XU J, Li S
Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
Blood. 2017;129:2593.
PubMed

DOURADO KMC, Baik J, Oliveira VKP, Beltrame M, et al
Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
Blood. 2017;129:2526-2536.
PubMed Abstract available

WANG HY
Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
Blood. 2017;129:2592.
PubMed

LAMPSON BL, Yu L, Glynn RJ, Barrientos JC, et al
Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Blood. 2017;129:2581-2584.
PubMed

GORINI F, Azzimonti L, Delfanti G, Scarfo L, et al
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
PubMed Abstract available

April 2017

PARILLA M, Venkataraman G
The thin line between CML and CMML.
Blood. 2017;129:2456.
PubMed

RADICH J
Understanding CML, 1 cell at a time.
Blood. 2017;129:2339-2340.
PubMed

KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
PubMed Abstract available

DING W, LaPlant BR, Call TG, Parikh SA, et al
Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
PubMed Abstract available

VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
PubMed Abstract available

GARDNER RA, Finney O, Annesley C, Brakke H, et al
Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
PubMed Abstract available

HU S, Qian M, Zhang H, Guo Y, et al
Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162
PubMed

Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
Blood. 2017;129:2204.
PubMed

PORCHER C, Chagraoui H, Kristiansen MS
SCL/TAL1: a multifaceted regulator from blood development to disease.
Blood. 2017;129:2051-2060.
PubMed Abstract available

SOOD R, Kamikubo Y, Liu P
Role of RUNX1 in hematological malignancies.
Blood. 2017;129:2070-2082.
PubMed Abstract available

AVELLINO R, Delwel R
Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation.
Blood. 2017;129:2083-2091.
PubMed Abstract available

DE BRUIJN M, Dzierzak E
Runx transcription factors in the development and function of the definitive hematopoietic system.
Blood. 2017;129:2061-2069.
PubMed Abstract available

UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
PubMed Abstract available

BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
PubMed Abstract available

TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
PubMed Abstract available

LANDIER W, Chen Y, Hageman L, Kim H, et al
Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
Blood. 2017;129:1919-1926.
PubMed Abstract available

DOWSE RT, Ireland RM
Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL.
Blood. 2017;129:2038.
PubMed

March 2017

GO RS, Winters JL, Kay NE
How I treat autoimmune hemolytic anemia.
Blood. 2017 Mar 30. pii: blood-2016-11-693689. doi: 10.1182/blood-2016-11-693689
PubMed Abstract available

GREENBERG PL
The classical nature of distinctive CMML monocytes.
Blood. 2017;129:1745-1746.
PubMed

FALANGA A
Predicting APL lethal bleeding in the ATRA era.
Blood. 2017;129:1739-1740.
PubMed

TALATI C, Zhang L, Shaheen G, Kuykendall A, et al
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
Blood. 2017;129:1881-1883.
PubMed

GEYER MB, Hsu M, Devlin SM, Tallman MS, et al
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
Blood. 2017;129:1878-1881.
PubMed

BACHEGOWDA LS, Saliba RM, Ramlal R, Kongtim P, et al
Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.
Blood. 2017 Mar 28. pii: blood-2017-02-766154. doi: 10.1182/blood-2017-02-766154
PubMed

GARZON R, Savona M, Baz R, Andreeff M, et al
A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
PubMed Abstract available

FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973
PubMed

CHENG CK, Wang AZ, Wong TH, Wan TS, et al
FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707
PubMed

FRISMANTAS V, Dobay MP, Rinaldi A, Tchinda J, et al
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Blood. 2017;129:e26-e37.
PubMed Abstract available

WONG TN, Link DC
miR-125b promotes leukemogenesis via VEGFA.
Blood. 2017;129:1409-1410.
PubMed

MERTENS D, Stilgenbauer S
Ibrutinib-resistant CLL: unwanted and unwonted!
Blood. 2017;129:1407-1409.
PubMed

SHAFAT MS, Oellerich T, Mohr S, Robinson SD, et al
Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
Blood. 2017;129:1320-1332.
PubMed Abstract available

SCHURINGA JJ
Smart niche usage: release its fat and burn it!
Blood. 2017;129:1239-1240.
PubMed

DUNCAVAGE EJ, Uy GL, Petti AA, Miller CA, et al
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Blood. 2017;129:1397-1401.
PubMed

GIRARDI T, Vicente C, Cools J, De Keersmaecker K, et al
The genetics and molecular biology of T-ALL.
Blood. 2017;129:1113-1123.
PubMed Abstract available

HUGHES A, Clarson J, Tang C, Vidovic L, et al
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Blood. 2017;129:1166-1176.
PubMed Abstract available

KNAPPER S, Russell N, Gilkes A, Hills RK, et al
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood. 2017;129:1143-1154.
PubMed Abstract available

SCHEINBERG DA
Immune reconstitution and remission in CML.
Blood. 2017;129:1064-1065.
PubMed

STONE RM
3 + 7 + FLT3 inhibitors: 1 + 1 not equal 2.
Blood. 2017;129:1061-1062.
PubMed

ALDOSS I, Song JY
Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
Blood. 2017;129:1231.
PubMed

SEHN LH, Soulier J
Introduction to the review series on T-cell malignancies.
Blood. 2017;129:1059-1060.
PubMed

LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
Blood. 2017;129:1227-1230.
PubMed

February 2017

AGARWAL P, Zhang B, Ho Y, Cook A, et al
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
Blood. 2017;129:1008-1020.
PubMed Abstract available

KORN C, Mendez-Ferrer S
Myeloid malignancies and the microenvironment.
Blood. 2017;129:811-822.
PubMed Abstract available

LANEUVILLE P
Stopping second-generation TKIs in CML.
Blood. 2017;129:805-806.
PubMed

POURABDOLLAH M, Chang H
Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
Blood. 2017;129:918.
PubMed

REITER A, Gotlib J
Myeloid neoplasms with eosinophilia.
Blood. 2017;129:704-714.
PubMed Abstract available

MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Blood. 2017;129:759-770.
PubMed Abstract available

ALSULIMAN A, Muftuoglu M, Khoder A, Ahn YO, et al
A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
Blood. 2017;129:740-758.
PubMed Abstract available

LOWENBERG B
Introduction to the Review Series on Leukemic Stem Cells.
Blood. 2017 Feb 3. pii: blood-2017-01-753319. doi: 10.1182/blood-2017-01-753319.
PubMed

COMOLI P, Basso S, Riva G, Barozzi P, et al
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
Blood. 2017;129:582-586.
PubMed Abstract available

PRATZ KW, Levis M
How I treat FLT3-mutated AML.
Blood. 2017;129:565-571.
PubMed Abstract available

LULLA P, Heslop HE
Fall of the mutants: T cells targeting BCR-ABL.
Blood. 2017;129:539-540.
PubMed

January 2017

DOHNER H, Estey E, Grimwade D, Amadori S, et al
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017;129:424-447.
PubMed Abstract available

CHESNAIS V, Arcangeli ML, Delette C, Rousseau A, et al
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Blood. 2017;129:484-496.
PubMed Abstract available

WARFVINGE R, Geironson Ulfsson L, Sommarin MN, Lang S, et al
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Blood. 2017 Jan 25. pii: blood-2016-07-728873. doi: 10.1182/blood-2016-07-728873
PubMed Abstract available

MUCHTAR E, Magen H, Gertz MA
How I treat cryoglobulinemia.
Blood. 2017;129:289-298.
PubMed Abstract available

ALI ND, Weissmann D
Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
Blood. 2017;129:394.
PubMed

VAINCHENKER W, Plo I
P53 deletion and NrasG12D cooperate for AML.
Blood. 2017;129:271-273.
PubMed

ASKEW D, Pareek TK, Eid S, Ganguly S, et al
Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
Blood. 2017;129:246-256.
PubMed Abstract available

ABU ZAID M, Wu J, Wu C, Logan BR, et al
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
Blood. 2017;129:162-170.
PubMed Abstract available

TARAFDAR A, Hopcroft LE, Gallipoli P, Pellicano F, et al
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Blood. 2017;129:199-208.
PubMed Abstract available

NICOLINI FE
CML stem cells: evasion for better invasion.
Blood. 2017;129:141-142.
PubMed

LEE LY, Hernandez D, Rajkhowa T, Smith SC, et al
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Blood. 2017;129:257-260.
PubMed

WALTER MJ
Antecedent CHIP in CML?
Blood. 2017;129:3-4.
PubMed

December 2016

STRAMUCCI L, Perrotti D
Twisting IL-1 signaling to kill CML stem cells.
Blood. 2016;128:2592-2593.
PubMed

November 2016

WILLIAMS KM
How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Blood. 2016 Nov 16. pii: blood-2016-08-693507.
PubMed Abstract available

CUSAN M, Vegi NM, Mulaw MA, Bamezai S, et al
Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.
Blood. 2016 Nov 8. pii: blood-2016-04-706978.
PubMed Abstract available

NEFF JL, Chen D
Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
Blood. 2016;128:2275.
PubMed

August 2016

COOMBS J, Bera E
B cells mimicking blasts after an allogeneic stem cell transplantation.
Blood. 2016;128:881.
PubMed

February 2016

TEIRA P, Battiwalla M, Ramanathan M, Barrett AJ, et al
Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis.
Blood. 2016 Feb 16. pii: blood-2015-11-679639.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: